Volume 5

## Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

(section 4)

## Part 1 – Table 1

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3599	P-ALPHA-DIMETHYL STYRENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3600	P-ANISIC ACID	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 0.3%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3601	PADIMATE O	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 8%.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3602	PADINA PAVONICA THALLUS PHYTOSTEROLS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.01%.
3603	PAEONIA LACTIFLORA	A, E, H	
3604	PAEONIA OBOVATA	A, H	
3605	PAEONIA SUFFRUTICOSA	A, E, H	
3606	PAEONIA VEITCHII	A, H	
3607	PALIURUS SPINA-CHRISTI	A, H	
3608	PALLADIUM	Н	Only for use as an active homoeopathic ingredient.
3609	PALM FRUIT OIL	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3610	PALM GLYCERIDES	Е	
3611	PALM KERNEL OIL	A, E, H	
3612	PALM TOCOTRIENOLS COMPLEX	A, H	
3613	PALMARIA PALMATA	A, H	
3614	PALMAROSA OIL	A, E, H	
3615	PALMITIC ACID	Е	
3616	PALMITOLEIC ACID-RICH FATTY ACID ETHYL ESTERS	A	
3617	PALMITOYL DIPEPTIDE-7	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.002%.
3618	PALMITOYL HYDROXYPROPYLTRIMONIUM AMYLOPECTIN/GLYCERIN CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.01%

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3619	PALMITOYL OLIGOPEPTIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.002%.
3620	PALMITOYL PENTAPEPTIDE-3	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.0005%.
3621	PALMITOYL TETRAPEPTIDE-3	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.001%.
3622	PANAX GINSENG	A, E, H	
3623	PANAX JAPONICUS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3624	PANAX NOTOGINSENG	A, H	
3625	PANAX PSEUDOGINSENG	A, H	
3626	PANAX QUINQUEFOLIUS	A, H	
3627	PANICUM MILIACEUM	A, H	
3628	PANTETHINE	Е	Only for use in topical medicines for dermal application.
3629	PANTHENOL	A, E	
3630	PANTHENYL ETHYL ETHER	E	Only for use in topical medicines for dermal application.
3631	PANTOLACTONE	E	
3632	PANTOTHENIC ACID	A, E	When used topically, the concentration in the medicine must be no more than 0.1%.
3633	PANTOTHENIC ACID POLYPEPTIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3634	PAPAIN	A, E	
3034	TATAIN	·	
3635	PAPER	E	Only for use in topical medicines for dermal application.
3636	PAPRIKA OLEORESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3637	PARA-CRESOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3638	PARA-CRESYL ACETATE	E	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3639	PARA-CRESYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3640	PARA-CRESYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3641	PARA-CYMENE	E	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a
3642	PARA- ETHOXYBENZALDEHYDE	Е	Permitted for use only in combination with other
	ETHOATBENZALDEHTDE		permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3643	PARA-ETHYLPHENOL	E	Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.  The maximum recommended deily does must contain no
			daily dose must contain no more than 0.12 mg of paraethylphenol.  The total flavour proprietary excipient formulation in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
3644	PARA-HYDROXY BENZALACETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3645	PARA-HYDROXYBENZOIC ACID	Е	
3646	PARA-MENTHA-8-THIOL-3-ONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3647	PARA-METHYL ACETOPHENONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3648	PARA-METHYL ANISOLE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3649	PARA-METHYL DIMETHYLBENZYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3650	PARA-PROPYL ANISOLE	E	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3651	PARA-TERT- BUTYLCYCLOHEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3652	PARA-TERT-BUTYLPHENYL-ALPHA-METHYLHYDROCINNAMIC ALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3653	PARA-TOLUALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3654	PARA-TOLYL ACETALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3655	PARAMERIA LAEVIGATA	А, Н	
3656	PARIETARIA JUDAICA	A, H	
3657	PARIS POLYPHYLLA	A, H	
3658	PARIS QUADRIFOLIA	A, H	
3659	PARSLEY	E, H	
3660	PARSLEY HERB DRY	A, E, H	
3661	PARSLEY HERB OIL	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3662	PARSLEY HERB POWDER	A, E, H	
3663	PARSLEY SEED OIL	A, E, H	
3664	PARTHENOCISSUS TRICUSPIDATA	A, H	
3665	PARTIALLY HYDROGENATED SOYA OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
3666	PARTIALLY REFINED PORPHYRA YEZOENSIS CYTOPLASM EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.00002%.
3667	PASPALUM NOTATUM	A, H	
3668	PASSIFLORA CAERULEA	A, H	
3669	PASSIFLORA EDULIS	Е	
3670	PASSIFLORA HERB DRY	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3671	PASSIFLORA INCARNATA	A, E, H	
3672	PATCHOULI OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3673	PATENT BLUE V	E	Permitted for use only as a colour for oral and topical use.
3674	PATENT BLUE V ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
3675	PATRINIA SCABIOSIFOLIA	A, H	
3676	PATRINIA VILLOSA	A, H	
3677	PAULLINIA CUPANA	A, E, H	Caffeine is a mandatory component of Paullinia cupana when used for oral ingestion.  When the route of administration is oral or sublingual and the medicine provides a maximum

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			recommended daily dose of more than 1 mg but no more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:
			- (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.'
			When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:  - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
3678	PAULLINIA PINNATA	A, H	
3679	PAWPAW	E	
3680	PEA	Е	
3681	PEA STARCH	Е	
3682	PEACH	Е	
3683	PEANUT	E	The medicine requires the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			following warning statement on the medicine label:
			- (PEANUT) 'Contains Peanut' (or words to that effect).
3684	PEAR	E	
3685	PECAN	E	
3686	PECTIN	A, E	
3687	PEG-10 DIMETICONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.  The concentration in the medicine must be no more than 4.0%.
3688	PEG-10 SOYA STEROL	Е	Only for use in topical medicines for dermal application.
3689	PEG-100 STEARATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3690	PEG-12 DILAURATE	E	
3691	PEG-12 DIMETICONE/PPG-20 CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 2%.
3692	PEG-120 METHYL GLUCOSE DIOLEATE	E	Only for use in topical medicines for dermal application.
3693	PEG-120 STEARATE	E	Only for use in topical medicines for dermal application.
3694	PEG-15 COCAMINE	E	Only for use in topical medicines for dermal application.
3695	PEG-150 DISTEARATE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3696	PEG-20 ALMOND GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
3697	PEG-20 METHYL GLUCOSE DISTEARATE	E	Only for use in topical medicines for dermal application.
3698	PEG-20 METHYL GLUCOSE SESQUISTEARATE	E	Only for use in topical medicines for dermal application.
3699	PEG-20 SORBITAN ISOSTEARATE	E	Only for use in topical medicines for dermal application.
3700	PEG-20 STEARATE	E	Only for use in topical medicines for dermal application.
3701	PEG-25 PABA	A	Only for use as an active ingredient in sunscreens for

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 10%.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3702	PEG-30 DIPOLYHYDROXYSTEARATE	E	Only for use in topical medicines for dermal application.
3703	PEG-30 STEARATE	E	Only for use in topical medicines for dermal application.
3704	PEG-35 CASTOR OIL	E	
3705	PEG-4 DILAURATE	E	Only for use in topical medicines for dermal application.
3706	PEG-4 LAURATE	E	Only for use in topical medicines for dermal application.  Dioxane and Ethylene oxide are mandatory components of PEG-4 laurate.  The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.  The concentration of Ethylene

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.
3707	PEG-4 STEARATE	E	Only for use in topical medicines for dermal application.
3708	PEG-40 CASTOR OIL	E	
3709	PEG-40 HYDROGENATED CASTOR OIL	E	
3710	PEG-40 SORBITAN DIISOSTEARATE	E	Only for use in topical medicines for dermal application.  Dioxane and Ethylene oxide are mandatory components of PEG-40 sorbitan diisostearate.  The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.  The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.
3711	PEG-40 STEARATE	E	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
3712	PEG-45/DODECYL GLYCOL COPOLYMER	Е	Only for use in topical medicines for dermal application.
3713	PEG-5 GLYCERYL STEARATE	E	Only for use in topical medicines for dermal application.
3714	PEG-50 STEARATE	Е	Only for use in topical medicines for dermal application.
3715	PEG-55 PROPYLENE GLYCOL OLEATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.6%.
3716	PEG-6 LAURAMIDE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3717	PEG-60 ALMOND GLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration when used in medicines applied directly to the skin must be no more than 10%.  The concentration when used in bath oil medicines must be no more than 30%.
3718	PEG-60 GLYCERYL ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.
3719	PEG-60 HYDROGENATED CASTOR OIL	E	Only for use in topical medicines for dermal application.
3720	PEG-7 COCAMIDE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3721	PEG-7 GLYCERYL COCOATE	Е	Only for use in topical medicines for dermal application.
3722	PEG-7 HYDROGENATED CASTOR OIL	E	Only for use in topical medicines for dermal application.
3723	PEG-75 LANOLIN	E	Only for use in topical medicines for dermal application.
3724	PEG-75 STEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.
3725	PEG-8 CETYL DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			0.0005%.
3726	PEG-8 DILAURATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.
3727	PEG-8 DISTEARATE	Е	Only for use in topical medicines for dermal application.
3728	PEG-8 LAURATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.  The levels of possible impurities such as ethylene oxide (and related material) must be kept below the level of detection.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3729	PEG-8 PROPYLENE GLYCOL COCOATE	Е	
3730	PEG-8 STEARATE	Е	Only for use in topical medicines for dermal application.
3731	PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 3.5%.
3732	PEG/PPG-14/7 DIMETHYL ETHER	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 7%.
3733	PEG/PPG-18/18 DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%.
3734	PELARGONIUM GRAVEOLENS	A, E, H	
3735	PELLITORINE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total
			flavour concentration in a medicine must be no more than 5%.
3736	PELTIGERA CANINA	A, H	
3737	PENICILLIUM EXPANSUM	A, H	
3738	PENNYROYAL OIL	Е	D-Pulegone/Pulegone is a mandatory component of Pennyroyal Oil.
			The concentration of D Pulegone/ Pulegone in the medicine must be no more than 4%.
			Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.  If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.  When the medicine is for a use other than topical, the maximum recommended daily dose must be no more than 50 mg of Pennyroyal Oil.
3739	PENTAERYTHRITYL TETRA-DI- T-BUTYL HYDROXYHYDROCINNAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.018%
3740	PENTAERYTHRITYL TETRAISOSTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 61%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3741	PENTAERYTHRITYL TETRALAURATE	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 80%.
3742	PENTAMETHYLHEPTENONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3743	PENTANE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3744	PENTASODIUM ETHYLENEDIAMINE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	TETRAMETHYLENE PHOSPHONATE		application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
3745	PENTYLENE GLYCOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
3746	PEPPER BLACK	E, H	
3747	PEPPER OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3748	PEPPER WHITE	E, H	
3749	PEPPERMINT AMERICAN EXT.	Е	Menthol is a mandatory component of peppermint

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			american ext.  When the medicine is for topical use:  a) the medicine must not be intended for use in the eye or on damaged skin;  b) the maximum concentration of menthol must not exceed 5%; and  c) the following warning statements are required on the medicine label:  - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;  - (IRRIT) If irritation develops, discontinue use; and  - (EYE) Avoid contact with eyes (or words to that effect).  When the medicine is for
			internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3750	PEPPERMINT LEAF DRY	A, E, H	When the ingredient is included in a medicine that is listed in the Register:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);
			- before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or
			- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).
			a) Menthol is a mandatory component of peppermint leaf dry.
			b) When the medicine is for topical use:
			(i) the medicine must not be intended for use in the eye or on damaged skin;
			(ii) the maximum concentration of menthol must not exceed 5%; and
			(iii) the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (IRRIT) If irritation develops, discontinue use; and
			- (EYE) Avoid contact with eyes (or words to that effect).
			c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3751	PEPPERMINT LEAF POWDER	A, E, H	When the ingredient is included in a medicine that is listed in the Register:  - on or after 1 July 2018, the medicine must comply with all
			requirements under (a)-(c);  - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or
			- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).
			a) Menthol is a mandatory component of peppermint leaf powder.
			b) When the medicine is for

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			topical use:  (i) the medicine must not be intended for use in the eye or on damaged skin;  (ii) the maximum concentration of menthol must not exceed 5%; and  (iii) the following warning statements are required on the medicine label:  - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;  - (IRRIT) If irritation develops, discontinue use; and  - (EYE) Avoid contact with eyes (or words to that effect).  c) When the medicine is for
			internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3752	PEPPERMINT OIL	A, E, H	When the ingredient is included in a medicine that is listed in the Register:  - on or after 1 July 2018, the medicine must comply with all

	Column 2	Column 3	Column 4
I	ngredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			requirements under (a)-(c);  - before 1 July 2018, and supplied on or after 1 January 2020 the medicine must comply with all requirements under (a)-(c); or  - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).  a) Menthol is a mandatory component of peppermint oil.  b) When the medicine is for topical use:  (i) the medicine must not be intended for use in the eye or on damaged skin;  (ii) the maximum concentration of menthol must not exceed 5%; and  (iii) the following warning statements are required on the medicine label:  - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;  - (IRRIT) If irritation develops, discontinue use; and

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (EYE) Avoid contact with eyes (or words to that effect).  c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3753	PEPPERMINT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation.  The total flavour proprietary excipient formulation in a medicine must be no more than 5%.  The total fragrance proprietary excipient formulation in a medicine must be no more 1%.  Menthol is a mandatory component of peppermint oil terpeneless.  When the medicine is for topical use:  a) the medicine must not be intended for use in the eye or on damaged skin;  b) the maximum concentration

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			of menthol must not exceed 5%; and
			c) the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develops, discontinue use; and
			- (EYE) Avoid contact with eyes (or words to that effect).
			When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
3754	PEPPERMINT OIL TERPENES AND TERPENOIDS	Е	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation.
			The total flavour proprietary excipient formulation in a medicine must be no more than 5%.
			Menthol is a mandatory component of peppermint oil

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			terpenes and terpenoids.  When the medicine is for topical use:  a) the medicine must not be intended for use in the eye or on damaged skin;  b) the maximum concentration of menthol must not exceed 5%; and  c) the following warning statements are required on the medicine label:  - (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;  - (IRRIT) If irritation develops, discontinue use; and  - (EYE) Avoid contact with eyes (or words to that effect).  When the medicine is for internal use, the maximum
			recommended daily dose must not contain more than 1 gram of menthol.
3755	PERFLUOROPOLYMETHYLISOP ROPYL ETHER	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3756	PERHYDRO-3,6-DIMETHYL- BENZO [B] FURAN-2-ONE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3757	PERILLA FRUTESCENS	A, E, H	Rosmarinic acid and vicenin-2 are only permitted for use if the plant part of Perilla frutescens is leaf.
3758	PERILLALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3759	PERLITE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.
3760	PERMETHRIN	Е	The concentration of in the medicine must be no more than 2%.
3761	PERSEA AMERICANA	A, E, H	
3762	PERSIC OIL	A, E, H	Amygdalin and Hydrocyanic acid are mandatory components of Persic oil.  The concentration of amygdalin in the medicine must be no more than 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
3763	PERSICARIA CHINENSIS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3764	PERSICARIA TINCTORIA	A, H	
3765	PERSIMMON	E	
3766	PERU BALSAM	A, E, H	
3767	PERU BALSAM OIL	A, E, H	
3768	PETITGRAIN MANDARIN OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour  The final concentration of the oil in the flavour does not exceed 30%  If used in a flavour the total flavour concentration in a medicine must be no more than 5%
3769	PETITGRAIN OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3770	PETITGRAIN OIL CITRONNIER	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.  When included in a medicine for use on the lips the concentration of petitgrain oil citronnier must be no more than 0.1%.  When included in dermal creams for infant use the concentration of petitgrain oil citronnier must be no more than 0.5%  The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
3771	PETITGRAIN OIL PARAGUAY	A, E, H	When used internally, oxedrine is a mandatory component of petitgrain oil paraguay.  The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3772	PETITGRAIN OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3773	PETROSELINUM CRISPUM	A, E, H	
3774	PEUCEDANUM PRAERUPTORUM	A, E, H	
3775	PEUMUS BOLDUS	A, H	Volatile oil components (of Peumus boldus) is a mandatory component.  The maximum recommended daily dose must be no more than 100 mg of volatile oil components (of Peumus boldus).
3776	PHALARIS ARUNDINACEA	A, H	
3777	PHALARIS CANARIENSIS	A, H	
3778	PHASEOLUS COCCINEUS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3779	PHASEOLUS VULGARIS	A, H	
3780	PHELLINUS ROBINIAE	A, E, H	
3781	PHELLODENDRON AMURENSE	A, E, H	
3782	PHELLODENDRON CHINENSE	A, H	
3783	PHENACETIN	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 0.1%.
3784	PHENETHYL 2- METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3785	PHENETHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3786	PHENETHYL ALCOHOL	E	Permitted for use only:  a) in topical medicines for dermal application; and  b) for internal use in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.  The total flavour proprietary excipient formulation concentration in a medicine must be no more than 5%.
3787	PHENETHYL BENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 6%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3788	PHENETHYL DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.2%
3789	PHENETHYL ISOAMYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3790	PHENETHYL ISOBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3791	PHENETHYL ISOVALERATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3792	PHENETHYL PHENYLACETATE	E	Permitted for use only in
3172			combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3793	PHENETHYL SALICYLATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3794	PHENOL	E	Only for use in topical medicines for dermal application.
			The concentration of phenol in the medicine must be no more than 1%.
3795	PHENOXYACETALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3796	PHENOXYETHANOL	Е	Only for use in topical medicines for dermal application.
			The concentration of phenoxyethanol in the preparation must not exceed

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			15%.
3797	PHENOXYETHYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3798	PHENOXYETHYLPARABEN	E	Only for use in topical medicines for dermal application.
3799	PHENYL DIMETHICONE	E	Only for use in topical medicines for dermal application.
3800	PHENYL TRIMETHICONE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3801	PHENYLACETALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3802	PHENYLACETALDEHYDE DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3803	PHENYLACETALDEHYDE GLYCERYLACETAL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
3804	PHENYLACETIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3805	PHENYLALANINE	A, E	When for oral ingestion the medicine requires the following warning statement on the medicine label:  - (PKU) 'Phenylketonurics are warned that this medicine contains phenylalanine' (or words to that effect).  When the medicine contains more than 500mg in the maximum recommended daily dose it requires the following warning statement on the medicine label:  - (PREGNT2) 'Do not use if pregnant or likely to become

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			pregnant'.
3806	PHENYLBENZIMIDAZOLE SULFONIC ACID	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			2019:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
3807	PHENYLETHYL BUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3808	PHENYLETHYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3809	PHENYLETHYL CAPRYLATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3810	PHENYLETHYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3811	PHENYLETHYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
3812	PHENYLETHYL METHYLETHYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3813	PHENYLETHYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3814	PHENYLETHYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
3815	PHENYLISOPROPYL DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
3816	PHENYLPROPANOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.16%.
3817	PHLEUM PRATENSE	A, H	
3818	PHLOXINE B	E	Permitted for use only as a colour for oral and topical use.
3819	PHLOXINE B ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3820	PHOENIX DACTYLIFERA	A, E, H	
3821	PHOSPHATIDYL CHOLINE	Е	
3822	PHOSPHOLIPIDS	E	Only for use in topical medicines for dermal application and not intended for use in the eye.  The concentration in the medicine must be no more than 20%.
3823	PHOSPHORIC ACID	E, H	The concentration in liquid medicines must be no more than 15%.
3824	PHOSPHORUS	Н	Only for use as an active homoeopathic ingredient.
3825	PHOTINIA SERRULATA	A, H	
3826	PHRAGMITES AUSTRALIS	A, H	
3827	PHYLLANTHUS AMARUS	A, H	
3828	PHYLLANTHUS EMBLICA	A, E, H	When used as an excipient, only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
			When ascorbic acid is claimed as a component the plant part is restricted to fruit.
3829	PHYLLOSTACHYS NIGRA	A, E, H	
3830	PHYSALIS ALKEKENGI	A, H	
3831	PHYSALIS PUBESCENS	A, H	
3832	PHYTANTRIOL	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 0.5%.
3833	PHYTOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3834	PHYTOLACCA AMERICANA	A, H	The maximum recommended daily dose of the medicine must contain no more than 1mg

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			of the equivalent dry herb.
3835	PHYTOMENADIONE	A, E	
3836	PHYTOSPHINGOSINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
3837	PHYTOSTERYL/OCTYLDODECY L LAUROYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
3838	PICEA ABIES	A, H	
3839	PICEA MARIANA	А, Н	
3840	PICRASMA EXCELSA	A, E, H	
3841	PICRORRHIZA KURROA	A, E, H	
3842	PIGMENT BLUE 15	Е	Permitted for use only as a colour for topical and dental

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			use.  The concentration in medicine must be no more than 0.003%.
3843	PIGMENT BLUE 15:1	E	Permitted for use only as a colour for topical use.  Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.21%.
3844	PIGMENT GREEN 7	E	Permitted for use only as a colour for topical and dental use.  When for dental use, the concentration in the medicine must be no more than 0.003%.  When for topical use, the concentration in the medicine must be no more than 0.17%.
3845	PIGMENT RED 4	E	Permitted for use only as a colour for topical use.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3846	PIGMENT RED 53	Е	Permitted for use only as a colour for topical use.
3847	PIGMENT RED 57	E	Permitted for use only as a colour for topical use.
3848	PIGMENT RED 57 ALUMINIUM LAKE	Е	Permitted for use only as a colour for topical use.
3849	PIGMENT RED 57 BARIUM LAKE	E	Permitted for excipient use as a colour in topical medicines for dermal application.  Not to be included in medicines intended for use in the eye.
3850	PIGMENT RED 63	E	Permitted for use only as a colour for topical use.
3851	PIGMENT WHITE 26	Е	Permitted for use only as a colour for topical use.
3852	PIGMENT YELLOW 12	Е	Permitted for use only as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			colour for topical use.
3853	PILOCARPUS JABORANDI	A, H	Pilocarpine is a mandatory component of Pilocarpus jaborandi.  The concentration of pilocarpine in the medicine must be no more than 0.025%.
3854	PILOCARPUS MICROPHYLLUS	A, H	Pilocarpine is a mandatory component of Pilocarpus microphyllus.  The concentration of pilocarpine in the medicine must be no more than 0.025%.
3855	PILOCARPUS PINNATIFOLIUS	A, H	Pilocarpine is a mandatory component of Pilocarpus pinnatifolius.  The concentration of pilocarpine in the medicine must be no more than 0.025%.
3856	PIMENTA FRUIT OIL	A, E, H	
3857	PIMENTA LEAF OIL	A, E, H	
3858	PIMENTA OFFICINALIS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3859	PIMENTA RACEMOSA	A, E, H	When the plant preparation for Pimenta racemosa is an oil and the concentration of this oil in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL.  When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container.  When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 25%, and the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container.  The medicine requires the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or word to that effect)  - (NTAKEN) 'Not to be taken'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3860	PIMPINELLA ANISUM	A, E, H	When the plant preparation for Pimpinella anisum is an oil or distillate and the concentration of this oil or distillate in the medicine is more than 50%: a) the nominal capacity of the container must be no more than 50 millilitres; and b) a restricted flow insert is must be fitted on the container; and c) the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
3861	PIMPINELLA SAXIFRAGA	A, E, H	
3862	PINE NEEDLE OIL SCOTCH	A, E, H	
3863	PINE NEEDLE OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
3864	PINE OIL AROMATIC	A, E, H	
3865	PINE OIL PUMILIO	A, E, H	
3866	PINEAPPLE	E	
3867	PINEAPPLE OILS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3868	PINELLIA TERNATA	A, H	
3869	PINUS CONTORTA	A, E, H	
3870	PINUS ELLIOTTII	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a
			medicine must be no more than 5%  If used in a fragrance the total fragrance concentration in a
			medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
3871	PINUS MASSONIANA	A, E, H	When the plant preparation is oil or distillate the total concentration of Pinus massoniana oil or distillate in the preparation must be no more than 25%.
3872	PINUS MONTICOLA	A, E, H	
3873	PINUS MUGO	A, E, H	
3874	PINUS PALUSTRIS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3875	PINUS PINASTER	A, E, H	When the plant preparation is oil or distillate the total concentration of Pinus pinaster oil or distillate in the preparation must be no more than 25%.
3876	PINUS PONDEROSA	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3877	PINUS RADIATA	A, E, H	
3878	PINUS STROBUS	A, E, H	
3879	PINUS SYLVESTRIS	A, E, H	
3880	PINUS TABULIFORMIS	A, E, H	
3881	PINUS YUNNANENSIS	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3882	PIPENZOLATE BROMIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3883	PIPER CHABA	A, E, H	
3884	PIPER CUBEBA	A, E, H	
3885	PIPER KADSURA	A, E, H	
3886	PIPER LONGUM	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3887	PIPER METHYSTICUM	А, Н	Kavalactones (of Piper methysticum) is a mandatory component of Piper methysticum.
			Only for oral use when the dosage form is 'tablet' or 'capsule'; or when the container type is 'tea bag'.
			When used in oral medicines, the maximum daily dose of kavalactones (of Piper methysticum) must be no more than 250 mg.
			If the dosage form is tablet or capsule then the quantity of kavalactones (of Piper methysticum) must be no more than 125 mg per tablet or capsule.
			Oral medicines containing more than 25 mg of kavalactones (of Piper methysticum) per dose require the following warning statement on the medicine label:
			- (PIPER) 'Not for prolonged use. If symptoms persist - seek advice from a healthcare practitioner. Not recommended for pregnant or lactating women (or words to that effect). May harm the liver'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The plant part must be root or rhizome.
			When for oral use, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.  When for topical use on the rectum, vagina or throat, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.
			When the container type is tea bag the maximum quantity per tea bag must be no more than 3 grams of dried whole or peeled root or rhizomes.
3888	PIPER NIGRUM	A, E, H	
3889	PIPER SARMENTOSUM	A, E, H	
3890	PIPERIDINE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total
			flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
3891	PIPERINE	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary formulation.  The total flavour proprietary formulation in a medicine must not be more than 5% and the concentration of piperine in the medicine must not be more than 0.15%.
3892	PIPERITONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3893	PIPERONAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
3894	PIPERONYL ACETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used as a flavour the total flavour concentration in a medicine must be no more than 5%.  If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3895	PIPERONYL BUTOXIDE	E	Only for use in topical medicines for dermal application.  The medicine requires the following warning statement on the medicine label:  - (PIPBUT) 'Contains piperonyl butoxide' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3896	PIROCTONE OLAMINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1% in wash-on/wash-off medicines and 0.5% in leave-on medicines.
3897	PISCIDIA PISCIPULA	A, E, H	
3898	PISTACIA LENTISCUS	A, E, H	
3899	PISUM SATIVUM	A, E, H	
3900	PLACENTA	Н	Only for use as an active homoeopathic ingredient.
3901	PLANTAGO AFRA	A, E, H	When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3902	PLANTAGO ARENARIA	А, Н	When a dose for children is stated and the plant part is flower, seed or pollen, the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3903	PLANTAGO ASIATICA	A, H	When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3904	PLANTAGO LANCEOLATA	A, E, H	The medicine requires the following warning statement on the medicine label:  - (CHILD5) 'Use in children under 3 years is not recommended'  When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3905	PLANTAGO MAJOR	A, E, H	When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3906	PLANTAGO OVATA	A, H	When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3907	PLANTAGO SEED DRY	A, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
3908	PLATANUS OCCIDENTALIS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3909	PLATANUS RACEMOSA	A, H	
3910	PLATANUS X ACERIFOLIA	A, H	
3911	PLATYCODON GRANDIFLORUS	A, E, H	
3912	PLECTRANTHUS BARBATUS	A, E, H	
3913	PLICATONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3914	PLUM	E	
3915	PLUMBAGO EUROPAEA	A, H	
3916	PLUMERIA ALBA	A, E, H	
3917	PLUMERIA RUBRA	A, E, H	
3918	POA NEMORALIS	A, H	
3919	POA PRATENSIS	A, H	
3920	PODOPHYLLUM PELTATUM	A, H	Podophyllin and podophyllotoxin are mandatory components of Podophyllum peltatum.  The concentration of podophyllin in the medicine must be no more than 1 mg/kg

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			or 1 mg/L or 0.0001%.  The concentration of podophyllotoxin in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
3921	POGOSTEMON CABLIN	A, E, H	
3922	POLACRILIN	Е	
3923	POLACRILIN POTASSIUM	E	
3924	POLAPREZINC	A	Only for use in oral medicines.  Zinc is a mandatory component of Polaprezinc.  The maximum recommended daily dose must be no more than 34 milligrams of zinc sourced from polaprezinc.  When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.  When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label:  - (ZINC) 'WARNING: May be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that effect).
3925	POLIGLUSAM	A, E	When for internal use, the following warning statements are required on the medicine label:
			- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect); and
			- (SFOOD) 'Derived from seafood'.
			When for internal use and the dosage form is a powdered preparation, the medicine requires the following warning statements on the medicine label:
			- (DNTPOW) 'Do not take powder alone. Mix with food or fluid'.
			When used as an excipient, only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.  In addition, when the ingredient is included in a medicine that is listed in the Register:  - on or after 1 July 2018, the medicine must comply with all requirements under (a) & (b);  - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a) & (b); or  - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a) & (b).  a) The average molecular mass of poliglusam must be greater than 2 kilodaltons.  b) When for internal use, the medicine must not contain more than 1750 milligrams of poliglusam per maximum recommended daily dose.
3926	POLIGLUSAM DERIVED FROM ASPERGILLUS NIGER	A, E	When for oral use, the medicine must provide no more than 2000 milligrams of Poliglusam derived from

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Aspergillus niger per maximum recommended daily dose and requires the following warning statement on the medicine label:
			- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).
			If the medicine is a powdered dosage form, the medicine also requires the following warning statement on the medicine label:
			- 'Do not take powder alone. Mix with food or fluid.'
			When used as an excipient, Poliglusam derived from Aspergillus niger is only permitted for use in topical medicines for dermal application.
3927	POLLACK-LIVER OIL	A, E	Colecalciferol and Vitamin A are mandatory components of Pollack-liver oil.
			When for use in topical medicines, the concentration of Vitamin A in the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			must be no more than 1%.  When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.  When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.
			- (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.  - (VITA3) 'The recommended
			daily amount of Vitamin A from all sources is 700

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
			When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.
3928	POLLEN	E	The medicine requires the following warning statement on the medicine label:  - (POLLEN) 'This medicine can cause severe allergic reactions' (or words to that effect).
3929	POLOXAMER	Е	Only for use in topical medicines for dermal application.
3930	POLOXAMINE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
3931	POLOXAMINE 1301	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
3932	POLY C10-30 ALKYL ACRYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.
3933	POLYACRYLAMIDE	Е	Only for use in topical medicines for dermal application.  Acrylamide is a mandatory component of Polyacrylamide.  The concentration of Acrylamide in the medicine must be no more than 0.01%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3934	POLYACRYLATE CROSSPOLYMER-6	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than
3935	POLYACRYLATE-1 CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.
3936	POLYACRYLIC ACID	E	The concentration in the medicine must be no more than 0.4%.
3937	POLYAMINO SUGAR CONDENSATE	E	Only for use in topical medicines for dermal application.
3938	POLYAMINOPROPYL BIGUANIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 0.3%.
3939	POLYBUTENE	Е	Only for use in topical medicines for dermal application.
3940	POLYBUTYLENE GLYCOL/PPG- 9/1 COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.
3941	POLYCAPROLACTONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
3942	POLYDECENE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 6%.
3943	POLYDEXTROSE	E	
3944	POLYDIETHYLSILOXANE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 5%.
3945	POLYDIMETHYL SILOXANE	E	Permitted for use only in combination with other permitted ingredients as a printing ink.  If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%
3946	POLYESTER-10	Е	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.
3947	POLYESTER-25	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 10%.
3948	POLYESTER-7	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
3949	POLYESTER-8	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration of Polyester-8 must be no more than 5%.
3950	POLYETHYLENE	E	
3951	POLYGALA CHINENSIS	A, H	
3952	POLYGALA SENEGA	A, E, H	Except when used in a medicine containing only homoeopathic preparations, a child resistant closure and restricted flow insert must be fitted onto the container.
3953	POLYGALA SIBIRICA	A, E, H	Only for use when the plant part is root or root bark.
3954	POLYGALA TENUIFOLIA	A	Only for use when the plant part is root or root bark.
3955	POLYGLYCERYL-10 PENTASTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3956	POLYGLYCERYL-2 DIISOSTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 3.0%.
3957	POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE	Е	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 5%.
3958	POLYGLYCERYL-2 TRIISOSTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  When the concentration of polyglyceryl-2 triisostearate is greater than 3%, the medicine must not be intended for use on damaged skin.  The concentration in the medicine must not be more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3959	POLYGLYCERYL-2-PEG-4 STEARATE	Е	Only for use in topical medicines for dermal application.
3960	POLYGLYCERYL-3 BEESWAX	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 0.5%.
3961	POLYGLYCERYL-3 DIISOSTEARATE	E	Only for use in topical medicines for dermal application.
3962	POLYGLYCERYL-3 DISTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
3963	POLYGLYCERYL-3 METHYLGLUCOSE	Е	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	DISTEARATE		included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 6%.
3964	POLYGLYCERYL-3 POLYDIMETHYLSILOXYETHYL DIMETHICONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5.5%.
3965	POLYGLYCERYL-3 POLYRICINOLEATE	Е	
3966	POLYGLYCERYL-3 STEARATE/ISOSTEARATE/DIME R DILINOLEATE CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 5%.
3967	POLYGLYCERYL-4 DIISOSTEARATE/POLYHYDROX	Е	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	YSTEARATE/SEBACATE		included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 3%.
3968	POLYGLYCERYL-4 ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
3969	POLYGLYCERYL-4 OLEATE	E	Only for use in topical medicines for dermal application.
3970	POLYGLYCERYL-6 POLYRICINOLEATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3971	POLYGLYCERYL-6 RICINOLEATE	Е	Only for use in topical medicines for dermal application.
3972	POLYGONATUM MULTIFLORUM	A, H	
3973	POLYGONATUM OFFICINALE	A, H	
3974	POLYGONATUM SIBIRICUM	A, E, H	
3975	POLYGONUM AVICULARE	A, E, H	When used as an excipient, the medicine is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.  When used as an excipient, the concentration in the medicine must be no more than 0.16%.
3976	POLYGONUM BISTORTA	A, H	
3977	POLYGONUM ODORATUM	A, H	
3978	POLYHYDROXYSTEARIC ACID	Е	Only for use in topical medicines for dermal application.
3979	POLYISOBUTYLENE	E	Only for use when the dosage form is 'chewing gum'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Must comply with: a) the Polyisobutylene monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.
3980	POLYISOPRENE	E	Only for use in topical medicines for dermal application.
3981	POLYLIMONENE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
3982	POLYMETHACRYLIC ACID	E	
3983	POLYMETHYL METHACRYLATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
3984	POLYMETHYLSILSESQUIOXAN E	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 3%.
3985	POLYPORUS UMBELLATUS	A, H	
3986	POLYPROPYLENE	Е	Only for use in topical medicines for dermal application.
3987	POLYPROPYLENE GLYCOL	Е	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation.  When used in a flavour, the
			total flavour proprietary excipient formulation in a medicine must be no more than 5%.  When used in a fragrance, the total fragrance proprietary excipient formulation in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
3988	POLYQUATERNIUM-10	E	Only for use in topical medicines for dermal application.
3989	POLYQUATERNIUM-11	E	Only for use in topical medicines for dermal application.
3990	POLYQUATERNIUM-22	E	Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than
3991	POLYQUATERNIUM-24	E	Only for use in topical medicines for dermal application.
3992	POLYQUATERNIUM-28	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
3993	POLYQUATERNIUM-37	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2.5%.
3994	POLYQUATERNIUM-44	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.3%.
3995	POLYQUATERNIUM-51	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
3996	POLYQUATERNIUM-7	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
3997	POLYSILICONE-11	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2.1%
3998	POLYSILICONE-14	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration of Polysilicone-14 must be no more than 1%.
3999	POLYSILICONE-15	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 10%.  When used in primary sunscreen products and listed

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4000	POLYSILICONE-2	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 0.13%.
4001	POLYSORBATE 20	E	
4002	POLYSORBATE 40	E	
4003	POLYSORBATE 60	Е	
4004	POLYSORBATE 65	Е	
4005	POLYSORBATE 80	Е	
4006	POLYSORBATE 85	Е	Only for use in topical medicines for dermal application.
4007	POLYTEF	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
4008	POLYURETHANE-34	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 2% in spray applications and 6% in non-spray applications.
4009	POLYURETHANE-62	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5%.
4010	POLYVINYL ACETATE	E	Only for use when the dosage form is chewing gum.
4011	POLYVINYL ACETATE PHTHALATE	E	
4012	POLYVINYL ALCOHOL	Е	
4013	POLYVINYL CHLORIDE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4014	POMEGRANATE	Е	
4015	PONCEAU SX	Е	Permitted for use only as a colour for topical use.
4016	PONCIRUS TRIFOLIATA	A, H	When used internally, oxedrine is a mandatory component of Poncirus trifoliata.  The quantity of Oxedrine in the maximum recommended daily dose must be no more than 30 mg.
4017	PONGAMOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.
4018	POPPY SEED	E, H	
4019	POPPY SEED OIL	E, H	
4020	POPULUS ALBA	A, H	
4021	POPULUS BALSAMIIFERA	A, E, H	
4022	POPULUS CANDICANS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4023	POPULUS DELTOIDES	A, H	
4024	POPULUS NIGRA	A, H	
4025	POPULUS TREMULA	A, H	
4026	POPULUS TREMULOIDES	A, H	
4027	PORCINE	Н	Only for use as an active homoeopathic ingredient.
4028	PORPHYRIDIUM PURPUREUM EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
4029	PORTULACA OLERACEA	A, E, H	
4030	POTABLE WATER	E	
4031	POTASSIUM ACETATE	E	
4032	POTASSIUM ARSENITE	Н	Only for use as an active homoeopathic ingredient.
4033	POTASSIUM ASCORBATE	A, E, H	When for oral or sublingual use, potassium is a mandatory component of potassium

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			ascorbate.
4034	POTASSIUM ASCORBATE DIHYDRATE	A, E, H	When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate dihydrate.
4035	POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE	Е	Only for use in topical medicines for dermal application.
4036	POTASSIUM ASPARTATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium aspartate.
4037	POTASSIUM ASPARTATE DIHYDRATE	A, E, H	If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate dihydrate. The percentage of potassium from potassium aspartate dihydrate

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			should be calculated based on the molecular weight of potassium aspartate dihydrate.
4038	POTASSIUM ASPARTATE MONOHYDRATE	A, E	If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate monohydrate. The percentage of potassium from potassium aspartate monohydrate should be calculated based on the molecular weight of potassium aspartate monohydrate.
4039	POTASSIUM BICARBONATE	Е	
4040	POTASSIUM BROMIDE	Н	Only for use as an active homoeopathic ingredient.
4041	POTASSIUM CARBONATE	E, H	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4042	POTASSIUM CETYL PHOSPHATE	Е	Only for use in topical medicines for dermal application.
4043	POTASSIUM CHLORIDE	A, E, H	When for oral use:
			a) potassium is a mandatory component of potassium chloride;
			b) the medicine requires the following warning statement on the medicine label:
			- (POTAS) 'Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'; and
			c) other than when used for oral rehydration therapy, the concentration must be no more than 550 mg per dosage unit.
			Medicines for use as oral rehydration therapy, are subject to the following conditions:
			a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Salts; b) the sodium, potassium and glucose content, and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Children's Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation' 18 July 2001; and c) the medicine requires the warning statements: - (UOAD) 'Use only as directed' - (DIAR3) 'If diarrhoea persists, seek medical advice.' When for dental use, the concentration in the medicine must be no more than 3.75%.
4044	POTASSIUM CITRATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium citrate.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4045	POTASSIUM COCOYL HYDROLYSED COLLAGEN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 10%.
4046	POTASSIUM COCOYL HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.15%.
4047	POTASSIUM DICHROMATE	Н	Only for use as an active homoeopathic ingredient.
4048	POTASSIUM GLUCONATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium gluconate.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4049	POTASSIUM GLYCEROPHOSPHATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium glycerophosphate.
4050	POTASSIUM HYDROXIDE	Е	The concentration in the medicine must be no more than 5%.  When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4051	POTASSIUM HYDROXYCITRATE	A, H	
4052	POTASSIUM IODATE	A, H	Iodine is a mandatory component of potassium iodate.  The percentage of iodine from potassium iodate should be calculated based on the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			molecular weight of potassium iodate.
			When for use in adults, the medicine must contain a daily dose of no more than 505 micrograms of potassium iodate.
			When for use in children aged 1-3 years, the medicine must contain a daily dose of no more than 337 micrograms of potassium iodate.
4053	POTASSIUM IODIDE	A, E, H	Iodine is a mandatory component of potassium iodide.  The percentage of iodine from potassium iodide should be calculated based on the molecular weight of potassium iodide.  When for internal use, the maximum recommended daily dose of the medicine must contains less than 300 micrograms of iodine.  When for external use, the concentration of iodine in the medicine (excluding salts derivatives or iodophors) must not exceed 2.5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4054	POTASSIUM METABISULFITE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4055	POTASSIUM METAPHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
4056	POTASSIUM NITRATE	A, H	Only for dental use.  The concentration in the medicine must be no more than 5%.
4057	POTASSIUM OROTATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			a mandatory component of potassium orotate.  When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4058	POTASSIUM PYROPHOSPHATE	E	Only for oral application, dental or topical use.  Not to be included in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 3%.
4059	POTASSIUM SORBATE	Е	The medicine requires the following warning statement on the medicine label:  - (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			to this effect) if medicine contains one sorbate source.
4060	POTASSIUM STANNATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4061	POTASSIUM STEARATE	Е	Only for use in topical medicines for dermal application.
4062	POTASSIUM SULFATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium sulfate.  When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH
			of the preparation must not exceed 11.5.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4063	POTATO STARCH	Е	
4064	POTENTILLA ANSERINA	A, H	
4065	POTENTILLA CHINENSIS	A, H	
4066	POTENTILLA DISCOLOR	A, H	
4067	POTENTILLA ERECTA	A, E, H	
4068	POTENTILLA REPTANS	A, H	
4069	POTERIUM OFFICINALE	A, E, H	
4070	POTERIUM SANGUISORBA	A, H	
4071	POVIDONE	E	
4072	POWDERED CELLULOSE	Е	
4073	PPG-1-PEG-9 LAURYL GLYCOL ETHER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4074	PPG-12/SMDI COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 2%.
4075	PPG-15 STEARYL ETHER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.
4076	PPG-15 STEARYL ETHER BENZOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.4%.
4077	PPG-17/IPDI/DMPA COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin.  The concentration of PPG-

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			17/IPDI/DMPA Copolymer in the medicine must be no more than 10%.
4078	PPG-2 LANOLIN ALCOHOL ETHER	E	Only for use in topical medicines for dermal application.
4079	PPG-2 MYRISTYL ETHER PROPIONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4080	PPG-20 LANOLIN ALCOHOL ETHER	Е	Only for use in topical medicines for dermal application.
4081	PPG-20 METHYL GLUCOSE ETHER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4082	PPG-20 METHYL GLUCOSE ETHER DISTEARATE	Е	Only for use in topical medicines for dermal application.
4083	PPG-3 HYDROGENATED CASTOR OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 6%.
4084	PPG-3 MYRISTYL ETHER	E	Only for use in topical medicines for dermal application.
4085	PPG-5-CETETH-20	Е	Only for use in topical medicines for dermal application.
4086	PPG-5-LAUROMACROGOL 250	E	Only for use in topical medicines for dermal application.
4087	PRALINE	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4088	PREGELATINISED MAIZE STARCH	Е	
4089	PREGELATINISED POTATO STARCH	Е	
4090	PREGELATINISED RICE STARCH	Е	
4091	PREGELATINISED WHEAT STARCH	E	When the route of administration is other than topical or mucosal, gluten is a mandatory component of pregelatinised wheat starch.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).
4092	PRENYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4093	PRICKLY ASH BARK DRY	A, H	
4094	PRICKLY ASH BARK POWDER	A, H	
4095	PRIMULA VERIS	A, E, H	
4096	PRIMULA VULGARIS	A, E, H	
4097	PRINSEPIA UNIFLORA	A, H	
4098	PROBOSCIDEA PARVIFLORA	A, H	
4099	PROGESTERONE	Н	Only for use as an active homoeopathic ingredient.
4100	PROLINE	A, E	
4101	PROPAN-1-OL	Е	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 18%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4102	DD OD ANG	T.	
4102	PROPANE	E	Only for use as an excipient propellant ingredient.
4103	PROPANEDIOL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 10%.
4104	PROPENYL GUAETHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4105	PROPIONALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4106	PROPIONIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4107	PROPIONYLLEVOCARNITINE HYDROCHLORIDE	A, H	
4108	PROPOLIS	A, E	Lead is a mandatory component of Propolis.  The concentration of lead in the medicine must be no more than 0.001%.  When used topically, the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine requires the following warning statement on the medicine label:  -(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'  When used for other than for topical, the medicine requires the following warning statement on the medicine label:  - (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4109	PROPOLIS BALSAM	A, E	Lead is a mandatory component of Propolis balsam.  The concentration of lead in the medicine must be no more than 0.001%.  When used topically, the medicine requires the following warning statement on the medicine label:  -(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'  When used for other than for topical, the medicine requires

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4110	PROPOLIS DRY EXTRACT	A, E	Lead is a mandatory component of Propolis dry extract.
			The concentration of lead in the medicine must be no more than 0.001%.
			When used topically, the medicine requires the following warning statement on the medicine label:
			-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'
			When used for other than for topical, the medicine requires the following warning statement on the medicine label:
			- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs,

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			discontinue use.'
4111	PROPOLIS LIQUID EXTRACT	A, E	Lead is a mandatory component of Propolis liquid extract.  The concentration of lead in the medicine must be no more than 0.001%.  When used topically, the medicine requires the following warning statement on the medicine label:  -(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'  When used for other than for topical, the medicine requires the following warning statement on the medicine label:  - (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4112	PROPOLIS RESIN	<b>A</b> , E	Lead is a mandatory component of propolis resin.  The concentration of lead in the medicine must be no more

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			than 0.001%.  When used topically, the medicine requires the following warning statement on the medicine label:  -(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'  When used for other than for topical, the medicine requires the following warning statement on the medicine label:  - (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4113	PROPOLIS TINCTURE	A, E	Lead is a mandatory component of Propolis tincture.  The concentration of lead in the medicine must be no more than 0.001%.  When used topically, the medicine requires the following warning statement on the medicine label:  -(PROP1) 'WARNING: Propolis may cause skin

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			irritation. Test before use'  When used for other than for topical, the medicine requires the following warning statement on the medicine label:  - (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'
4114	PROPYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4115	PROPYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4116	PROPYL GALLATE	Е	
4117	PROPYL HYDROXYBENZOATE	E	Medicines containing hydroxybenzoates require the following warning statement on the medicine label:  - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
4118	PROPYLENE CARBONATE	Е	Only for use in topical medicines for dermal application.
4119	PROPYLENE GLYCOL	Е	
4120	PROPYLENE GLYCOL ALGINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4121	PROPYLENE GLYCOL DIBENZOATE	E	Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 20%.
4122	PROPYLENE GLYCOL DIDECANOATE	E	Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.
4123	PROPYLENE GLYCOL DIOCTANOATE	Е	Only for use in topical medicines for dermal application.
4124	PROPYLENE GLYCOL DIOCTANOATE/DIDECANOATE	Е	Only for use in topical medicines for dermal application.
4125	PROPYLENE GLYCOL DIPELARGONATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4126	PROPYLENE GLYCOL ISOCETETH-3 ACETATE	E	Only for use in topical medicines for dermal
			application only and not to be used in topical medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1%.
4127	PROPYLENE GLYCOL ISOSTEARATE	E	Only for use in topical medicines for dermal application.
4128	PROPYLENE GLYCOL MONOLAURATE	E	Only for use in topical medicines for dermal application.
4129	PROPYLENE GLYCOL MONOSTEARATE	E	Only for use in topical medicines for dermal application.
4130	PROPYLENE GLYCOL MYRISTYL ETHER ACETATE	E	Only for use in topical medicines for dermal application.
4131	PROSOPIS JULIFLORA	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4132	PROTEASE	A	Must be derived from Aspergillus oryzae or Aspergillus niger.  When the dosage form is undivided, the units 'haemoglobin unit on the tyrosine basis per gram' and 'Thousand haemoglobin units on the tyrosine basis per gram' are permitted.  When the dosage form is divided, the units 'haemoglobin units on the tyrosine basis' and 'thousand haemoglobin units on the tyrosine basis' are permitted.
4133	PROTEIN HYDROLYSATE	Е	
4134	PRUNE JUICE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4135	PRUNE JUICE CONCENTRATE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4136	PRUNELLA VULGARIS	A, H	
4137	PRUNUS AFRICANA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus africana.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4138	PRUNUS ARMENIACA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus armeniaca and must be declared in the application.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1 microgram/kg or 1 microgram/L or 0.0000001%.
4139	PRUNUS AVIUM	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus avium.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4140	PRUNUS CERASIFERA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasifera.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4141	PRUNUS CERASUS	A, E, H	Amygdalin and hydrocyanic acid are mandatory

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			components of Prunus cerasus.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4142	PRUNUS DOMESTICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus domestica.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4143	PRUNUS DULCIS	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus dulcis when the plant part is seed.  When the plant part is seed, the maximum recommended daily dose must be no more than the equivalent of 1 mg of the dry

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			seed.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4144	PRUNUS HUMILIS	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus humilis.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4145	PRUNUS JAPONICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus japonica.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4146	PRUNUS LAUROCERASUS	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus laurocerasus.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4147	PRUNUS MUME	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus mume.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4148	PRUNUS PERSICA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus persica.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4149	PRUNUS SALICINA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus salicina.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4150	PRUNUS SEROTINA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus serotina.  The concentration of Amygdalin in the medicine must be 0%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4151	PRUNUS SPINOSA	A, E, H	Amygdalin and hydrocyanic acid are mandatory components of Prunus spinosa.  The concentration of Amygdalin in the medicine must be 0%.  The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.
4152	PRUSSIAN BLUE	E	Permitted for use only as a colour for topical use.
4153	PSEUDOCYDONIA SINENSIS	A, H	
4154	PSEUDOSTELLARIA HETEROPHYLLA	A, E, H	
4155	PSEUDOTSUGA MENZIESII	A, H	
4156	PSEUDOWINTERA COLORATA	А, Н	Only for use when the plant part is leaf.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4157	PSIDIUM GUAJAVA	A, E, H	
4158	PSORALEN (OF CULLEN CORYLIFOLIUM)	E	
4159	PSORINUM	Н	Only for use as an active homoeopathic ingredient.
4160	PSYLLIUM HUSK DRY	A, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
4161	PSYLLIUM HUSK POWDER	A, E, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:  - (PSYLL) 'On medical advice' (or words to that effect).
4162	PSYLLIUM SEED DRY	A, E, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (PSYLL) 'On medical advice' (or words to that effect).
4163	PTELEA TRIFOLIATA	A, H	
4164	PTEROCARPUS MARSUPIUM	A, H	
4165	PTEROCARPUS SANTALINUS	A, E, H	
4166	PUERARIA LOBATA	A, E, H	
4167	PUERARIA MONTANA VAR. LOBATA	A, E, H	
4168	PULLULAN	E	
4169	PUMICE	E	
4170	PUMPKIN	E	
4171	PUMPKIN SEED	E, H	
4172	PUMPKIN SEED OIL	E, H	
4173	PUNICA GRANATUM	A, E, H	
4174	PURE BEE VENOM	Н	Only for use as an active homoeopathic ingredient.
4175	PURIFIED HONEY	A, E	When the route of administration is oral, the medicine requires the following warning statement on the medicine label:  - (BABY2) 'Not suitable for

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			infants under the age of twelve months' (or words to that effect).
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:
			- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
4176	PURIFIED SILICEOUS EARTH	E, H	
4177	PURIFIED TALC	E	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4178	PURIFIED WATER	E	
4179	PVM/MA COPOLYMER	Е	
4180	PVM/MA DECADIENE CROSSPOLYMER	Е	Only for use in topical medicines for dermal application.
4181	PVP/EICOSENE COPOLYMER	E	Only for use in topical medicines for dermal application.
4182	PVP/HEXADECENE COPOLYMER	E	Only for use in topical medicines for dermal application.
4183	PYRETHRINS	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 10%.  The medicine requires the following warning statement on the medicine label:  - (PYRTH3) 'Contains pyrethrins [insert quantity]' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4184	PYRIDOXAL 5-PHOSPHATE	A, E	Pyridoxine is a mandatory component of Pyridoxal 5-phosphate.  The percentage of pyridoxine from pyridoxal 5-phosphate should be calculated based on the molecular weight of pyridoxal 5-phosphate.  The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.  If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:  - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4185	PYRIDOXAL 5-PHOSPHATE MONOHYDRATE	A	Pyridoxine is a mandatory component of Pyridoxal 5-phosphate monohydrate.
			The percentage of pyridoxine from pyridoxal 5-phosphate

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			monohydrate should be calculated based on the molecular weight of pyridoxal 5-phosphate monohydrate.  The maximum recommended daily dose must provide no more than 200 mg of
			pyridoxine.  If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:  - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4186	PYRIDOXINE HYDROCHLORIDE	A, E, H	When not used as an active homoeopathic ingredient, pyridoxine is a mandatory component of Pyridoxine hydrochloride.  The percentage of pyridoxine from pyridoxine hydrochloride should be calculated based on the molecular weight of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			pyridoxine hydrochloride.  The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.  If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:  - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'
4187	PYROGLUTAMIC ACID	E	
4188	PYROLA DECORATA	A, H	
4189	PYROLIGNEOUS ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4190	PYRROSIA LINGUA	A, H	
4191	PYRROSIA PETIOLOSA	A, H	
4192	PYRROSIA SHEARERI	A, H	
4193	PYRUS COMMUNIS	A, E, H	Arbutin is a mandatory component of Pyrus communis.  The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg/L or 0.0025 % unless used on the hair.  When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.
4194	PYRUS PYRIFOLIA	A, H	Arbutin is a mandatory component of Pyrus pyrifolia.  The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg/L or 0.0025 % unless used on the hair.  When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4195	PYRUVIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4196	QUASSIA	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4197	QUASSIA AMARA	A, E, H	
4198	QUASSIA WOOD JAMAICAN DRY	A, H	
4199	QUASSIA WOOD JAMAICAN POWDER	A, H	
4200	QUATERNIUM-15	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4201	QUATERNIUM-18 BENTONITE	Е	Only for use in topical medicines for dermal application.
4202	QUATERNIUM-18 HECTORITE	Е	Only for use in topical medicines for dermal application.
4203	QUATERNIUM-52	E	Only for use in wash-on/wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.  Not be used in medicines in which N-nitroso compounds may be formed.
4204	QUATERNIUM-80	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2.5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4205	QUERCETIN	A	
4206	QUERCETIN DIHYDRATE	A	
4207	QUERCUS ACUTISSIMA	A, H	
4208	QUERCUS ALBA	A, E, H	
4209	QUERCUS PALUSTRIS	A, H	
4210	QUERCUS ROBUR	A, H	
4211	QUERCUS RUBRA	A, H	
4212	QUERCUS VIRGINIANA	A, H	
4213	QUILLAIA DRY	A, H	
4214	QUILLAIA POWDER	A, E, H	
4215	QUILLAJA SAPONARIA	A, H	
4216	QUINCE	Е	
4217	QUININE ARSENITE	Н	Only for use as an active homoeopathic ingredient.  Quinine is a mandatory component of Quinine arsenite.  The maximum recommended daily dose must be no more than 50 mg of quinine.
4218	QUININE SULFATE DIHYDRATE	Н	Only for use as an active homoeopathic ingredient.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Quinine is a mandatory component of quinine sulfate dihydrate.
			The maximum recommended daily dose must be no more than 50 mg of quinine.
4219	QUINOLINE YELLOW	Е	Permitted for use only as a colour for oral and topical use.
4220	QUINOLINE YELLOW ALUMINIUM LAKE	Е	Permitted for use only as a colour for oral and topical use.
4221	QUISQUALIS INDICA	A, H	
4222	R-ALPHA LIPOIC ACID	A	
4223	RACEMENTHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4224	RACEMIC CAMPHOR	E, H	Only for use as an active homoeopathic or excipient ingredient.  In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.  In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.  In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect); and  - (NTAKEN) 'Not to be taken'.  In essential oil preparations, if
			the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'.
			In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and
			- (NTAKEN) 'Not to be taken'.
			If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
1225	D.A.DIGU		
4225	RADISH	E	
4226	RAISIN JUICE CONCENTRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4227	RANUNCULUS BULBOSUS	A, H	
4228	RANUNCULUS FICARIA	A, H	
4229	RANUNCULUS TERNATUS	A, H	
4230	RAPE OIL/TUNG OIL COPOLYMER	Е	Only for use in topical medicines for dermal application and not for use in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than
4231	RAPE SEED OIL	A, E, H	Allyl isothiocyanate is a mandatory component of rape seed oil when the plant part is seed.
			The concentration of allyl

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
4232	RAPHANUS SATIVUS	A, H	
4233	RASPBERRY	E	
4234	RASPBERRY BRANDY	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4235	RASPBERRY DISTILLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4236	RASPBERRY ESSENCE	E	Permitted for use only in combination with other permitted ingredients as a flavour.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4237	RASPBERRY JUICE CONCENTRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4238	RAUWOLFIA SERPENTINA	А, Н	The concentration of equivalent dry Rauwolfia serpentina in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4239	RAUWOLFIA SERPENTINA DRY	A, H	The concentration of Rauwolfia Serpentina Dry in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
4240	RAUWOLFIA SERPENTINA POWDER	А, Н	The concentration of Rauwolfia Serpentina Powder in the medicine must be no more than 10mg/Kg or 10mg/L

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			or 0.001%.
4241	RED 27	Е	Permitted for use only as a colour for oral and topical use.  The concentration in the medicine must be no more than 0.5%.
4242	RED 27 ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.  The concentration in the medicine must be no more than 0.5%.
4243	RED ANT	Н	Only for use as an active homoeopathic ingredient.
4244	RED CLOVER FLOWER DRY	A, H	
4245	RED CLOVER FLOWER POWDER	A, H	
4246	RED CORAL	Н	Only for use as an active homoeopathic ingredient.
4247	RED DEER	A	
4248	RED MERCURIC IODIDE	Н	Only for use as an active homoeopathic ingredient.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4249	RED MERCURIC OXIDE	Н	Only for use as an active homoeopathic ingredient.
4250	RED MERCURIC SULFIDE	Н	Only for use as an active homoeopathic ingredient.
4251	REHMANNIA GLUTINOSA	A, E, H	
4252	REL-1-((1R,2S)-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYL-2-NAPHTHALENYL)-1-ETHANONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4253	RESORCINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4254	RESORCINOL DIMETHYLETHER	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4255	RETINOL	A, E	Vitamin A is a mandatory component of retinol.  When for use in topical
			medicines, the concentration of Vitamin A in the medicine must be no more than 1%.  When for internal use, the maximum daily dose must be no more than 3000 micrograms
			of Retinol Equivalents.  When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.  - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.  - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4256	RETINOL ACETATE	A, E	Vitamin A is a mandatory component of retinol acetate.  When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.  When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.  When preparations for internal use in adults contain more than 33 micrograms of retinol

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:  - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.  - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.  - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4257	RETINOL PALMITATE	A, E	Vitamin A is a mandatory
4237	RETINOL PALIVITATE	A, E	component of retinol palmitate.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.
			When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.
			- (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4258	REYNOUTRIA JAPONICA	A, E, H	When used as an excipient, only for use in topical medicines for dermal application.
4259	RHAMNOSE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4260	RHAMNUS CATHARTICA	A, H	When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhamnus cathartica.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contains [name of the herb(s) or the chemical component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4261	RHAMNUS FRANGULA	A, H	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Rhamnus frangula.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contains [name of the herb(s) or the chemical component(s)]'; and - (LAX4) 'This product may
			have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and
42(2	DHATANY DOOT DRY	A II	- (LAX2) 'Prolonged use may cause serious bowel problems'.
4262	RHATANY ROOT DRY	A, H	
4263	RHATANY ROOT POWDER	A, H	
4264	RHEUM OFFICINALE	A, E, H	The plant part must not be leaf.  When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			mandatory component of Rheum officinale.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.
4265	RHEUM PALMATUM	A, E, H	The plant part must not be leaf.
			When the route of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum palmatum.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (LAX1) 'Drink plenty of water' (or words to that effect).  When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4266	RHEUM RHAPONTICUM	A, E, H	The plant part must not be leaf.  When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rheum rhaponticum.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems'; and  - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).  When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4267	RHEUM TANGUTICUM	A, H	The plant part must not be leaf.  When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum tanguticum.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems'; and  - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect);

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			and - (LAX2) 'Prolonged use may cause serious bowel problems'.
4268	RHODAMINE B	Е	Permitted for use only as a colour for topical use.
4269	RHODINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4270	RHODINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4271	RHODIOLA ROSEA	A	Only for use in oral medicines.  Only available for use when the plant preparation is dry root powder, dry root powder as an aqueous extract or dry root powder as a hydroethanolic extract with no more than 70% ethanol v/v.
4272	RHODODENDRON AUREUM	A, H	
4273	RHODODENDRON FERRUGINEUM	A, H	Arbutin is a mandatory component of Rhododendron ferrugineum.  The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg/L or 0.0025 % unless used on the hair.  When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.
4274	RHODODENDRON MOLLE	A, H	The maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.
4275	RHUBARB	E, H	When the route of administration is oral,

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Hydroxyanthracene derivatives is a mandatory component of Rhubarb.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			water' (or words to that effect).  When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4276	RHUBARB ROOT DRY	A, H	When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root dry.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may cause serious bowel problems'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4277	RHUBARB ROOT POWDER	A, H	When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root powder.
			When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX1) 'Drink plenty of water' (or words to that effect); and
			- (LAX2) 'Prolonged use may

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			cause serious bowel problems'.
4278	RHUS AROMATICA	A, E, H	
4279	RHUS CHINENSIS	A, H	
4280	RHUS GLABRA	A, E, H	
4281	RHUS VENENATA	Н	Only for use as an active homoeopathic ingredient.
4282	RIBES GROSSULARIA	A, E, H	
4283	RIBES NIGRUM	A, E, H	
4284	RIBOFLAVIN	A, E	
4285	RIBOFLAVIN SODIUM PHOSPHATE	A, E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4286	RIBOFLAVIN TETRAACETATE	E	Only for use in topical medicines for dermal

Column 2	Column 3	Column 4
Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
		application.
RIBOFLAVINE	A, E	
RIBOFLAVINE SODIUM PHOSPHATE	A, E	
RIBONUCLEIC ACID	E	Only for use in topical medicines for dermal application.
RIBOSE	A	Only for use in oral medicines.  When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.  If one of the sugars is lactose
	RIBOFLAVINE RIBOFLAVINE SODIUM PHOSPHATE	Ingredient Name  Purpose of the ingredient in the medicine  RIBOFLAVINE  RIBOFLAVINE SODIUM PHOSPHATE  RIBONUCLEIC ACID  E

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
4291	RICE	E	
4292	RICE BRAN	E	
4293	RICE BRAN OIL	E	
4294	RICE BRAN WAX	A, E, H	
4295	RICE STARCH	E	
4296	RICE VINEGAR	E	
4297	RICE WINE	E	Ethanol is a mandatory component of Rice wine.  When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label:  - (ETHAN) 'Contains ethanol' or 'contains alcohol'
4298	RICINOLEIC ACID	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4299	RICINUS COMMUNIS	A, H	Only for use when the plant part must be seed and the plant preparation is oil fixed.
4300	ROBINIA PSEUDOACACIA	A, E, H	When the herbal substance is derived from plant parts other than the leaf or flower, the maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.
4301	ROHDEA JAPONICA	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
4302	ROSA ARVENSIS	A, E, H	
4303	ROSA CANINA	A, E, H	
4304	ROSA CYMOSA	A, E, H	
4305	ROSA EGLANTERIA	A, E, H	
4306	ROSA GALLICA	A, E, H	
4307	ROSA LAEVIGATA	A, E, H	
4308	ROSA MULTIFLORA	A, E, H	
4309	ROSA ROXBURGHII FRUIT EXTRACT	Е	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.002%.
4310	ROSA RUGOSA	A, E, H	
4311	ROSA VILLOSA	A, E, H	
4312	ROSA X CENTIFOLIA	A, E, H	
4313	ROSA X DAMASCENA	A, E, H	
4314	ROSANA	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4315	ROSE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
4316	ROSE FRUIT FRESH	A, E, H	
4317	ROSE HIP	E	
4318	ROSE OIL	A, E, H	
4319	ROSE OXIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4320	ROSEMARY OIL	A, E, H	Safrole is a mandatory component of Rosemary oil.  When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.  When for topical use then the concentration of safrole in the medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4321	ROSMARINUS OFFICINALIS	A, E, H	Camphor and cineole are mandatory components of Rosmarinus officinalis.  In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.  In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.  When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres.  In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			of children' (or words to that effect); and  - (NTAKEN) 'Not to be taken'.  In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect); and  - (NTAKEN) 'Not to be taken'.  If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.
4322	ROYAL JELLY	A, E	10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The medicine requires the following warning statements on the medicine label:  - (CHILD2) 'Not suitable for children'  - (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.
4323	ROYAL JELLY FRESH	A, E	10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly fresh.  The medicine requires the following warning statements on the medicine label:  - (CHILD2) 'Not suitable for children'  - (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			asthma and allergy sufferers'.
4324	ROYAL JELLY LYOPHILISED	A, E	10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly lyophilised.  The medicine requires the following warning statements on the medicine label:  - (CHILD2) 'Not suitable for children'  - (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.
4325	RUBBER NATURAL	Е	Only for use in topical medicines for dermal application.
4326	RUBIA CORDIFOLIA	A, H	
4327	RUBIA TINCTORUM	A, H	
4328	RUBUS CHINGII	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4329	RUBUS CORCHORIFOLIUS	A, H	
4330	RUBUS COREANUS	A, E, H	
4331	RUBUS FRUTICOSUS	A, E, H	
4332	RUBUS IDAEUS	A, E, H	
4333	RUBUS OCCIDENTALIS	A, E, H	
4334	RUBUS PARVIFOLIUS	A, H	
4335	RUBUS ROSIFOLIUS	A, H	
4336	RUDBECKIA HIRTA	A, H	
4337	RUE OIL	A, H	
4338	RUM	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4339	RUMEX ACETOSA	A, H	
4340	RUMEX ACETOSELLA	A, H	
4341	RUMEX CONGLOMERATUS	A, H	
4342	RUMEX CRISPUS	A, E, H	
4343	RUMEX PULCHER	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4344	RUMEX SCUTATUS	A, H	
4345	RUSCUS ACULEATUS	A, H	
4346	RUTA GRAVEOLENS	A, E, H	
4347	RUTOSIDE	A, E	
4348	RYE	E	Gluten is a mandatory component of Rye when the route of administration is other than topical and mucosal.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).
4349	RYE BRAN	E	Gluten is a mandatory component of Rye bran when the route of administration is other than topical and mucosal.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			to that effect).
4350	S-ISOPROPYL 3- METHYLTHIOCROTONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4351	SABINENE HYDRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4352	SACCHARIDE ISOMERATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 3.66%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4353	SACCHARIN	Е	The medicine requires the following warning statement on the medicine label:  - (SACCH) 'Contains saccharin' (or words to that effect).
4354	SACCHARIN SODIUM	E	The medicine requires the following warning statement on the medicine label:  - (SACCH) 'Contains saccharin' (or words to that effect).  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4355	SACCHAROMYCES CEREVISIAE	A, E	When for topical use, the concentration in the medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4356	SACCHAROMYCES CEREVISIAE (BOULARDII)	A	
4357	SACCHAROMYCES CERVISIAE POLYSACCHARIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.
4358	SACCHAROMYCES/ZINC FERMENT	E	Only for use in topical medicines for dermal application.
4359	SACCHARUM OFFICINARUM	A, E, H	
4360	SAFFLOWER OIL	A, E, H	
4361	SAFFRON	E	Permitted for use only as a colour for either topical use or with an oral route of administration.
4362	SAGE LEAF DRY	A, E, H	Thujone is a mandatory component of Sage leaf dry.  The concentration of thujone in the medicine must be no more

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			than 4%.
4363	SAGE LEAF POWDER	A, H	Thujone is a mandatory component of Sage leaf powder.  The concentration of thujone in the medicine must be no more than 4%.
4364	SAGE OIL DALMATIAN	A	Thujone is a mandatory component of Sage oil dalmatian.  The concentration of thujone in the medicine must be no more than 4%.  When the concentration of Sage oil dalmatian in the medicine is more than 10% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert and child resistant closure must be fitted on the container and the medicine requires the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or word to that effect)  - (NTAKEN) 'Not to be taken'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4365	SAGE OIL SPANISH	A, E, H	
4366	SALICORNIA EUROPAEA EXTRACT	E	Only for use in topical medicines for dermal use and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 0.002%.
4367	SALICYLALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4368	SALICYLIC ACID	E, H	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 40%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4369	SALIX ALBA	A, E, H	
4370	SALIX DAPHNOIDES	A, H	
4371	SALIX DISCOLOR	A, H	
4372	SALIX FRAGILIS	A, H	
4373	SALIX NIGRA	A, H	
4374	SALIX PURPUREA	A, H	
4375	SALSOLA KALI	A, H	
4376	SALVIA CHINENSIS	A, H	
4377	SALVIA FRUTICOSA	A, H	
4378	SALVIA HISPANICA	A, E, H	
4379	SALVIA LAVANDULAEFOLIA	A, H	
4380	SALVIA MILTIORRHIZA	A, H	
4381	SALVIA OFFICINALIS	A, E, H	Thujone is a mandatory component of Salvia officinalis.  The concentration of thujone in the medicine must be no more than 4%.
4382	SALVIA SCLAREA	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4383	SAMBUCUS CANADENSIS	A, H	
4384	SAMBUCUS EBULUS	A, H	
4385	SAMBUCUS NIGRA	A, E, H	
4386	SANDALWOOD OIL EAST INDIAN	A, E, H	
4387	SANGUINARIA CANADENSIS	Н	Only for use as an active homoeopathic ingredient.  The potency must be more than 4X.
4388	SANICULA EUROPAEA	A, H	
4389	SANTALUM ALBUM	A, E, H	
4390	SANTALUM SPICATUM	A, E, H	The route of administration must be topical or inhalation.  The plant preparation must be oil.  The plant part must be root or stem wood including heartwood.
4391	SAPINDUS MUKOROSSI	A, H	
4392	SAPONARIA OFFICINALIS	A, H	
4393	SAPOSHNIKOVIA DIVARICATA	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4394	SARCOSINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
4395	SARGASSUM FUSIFORME	A, H	Iodine is a mandatory component of Sargassum fusiforme.  Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.  Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
4396	SARGASSUM SILIQUASTRUM	A, H	Iodine is a mandatory component of Sargassum siliquastrum.  Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			2.5% or less.  Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
4397	SASSAFRAS ALBIDUM	A, H	Safrole is a mandatory component of Sassafras albidum.  When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.  When for topical use then the concentration of safrole in the medicine must be no more than 1%.
4398	SATUREIA HORTENSIS	A, H	
4399	SATUREIA MONTANA	A, H	
4400	SAUROPUS SPATULIFOLIUS	A, H	
4401	SAURURUS CHINENSIS	A, H	
4402	SAUSSUREA COSTUS	A, H	
4403	SAVORY OIL SUMMER	A, H	
4404	SAXIFRAGA GRANULATA	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4405	SAXIFRAGA STOLONIFERA	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must not be more than 0.0816%.
4406	SCAPHIUM SCAPHIGERUM	A, H	
4407	SCHEFFLERA HEPTAPHYLLA	A, H	
4408	SCHINOPSIS QUEBRACHO- COLORADO	A, H	
4409	SCHINUS MOLLE	A, H	
4410	SCHINUS MOLLE OIL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4411	SCHISANDRA CHINENSIS	A, E, H	
4412	SCHIZONEPETA TENUIFOLIA	A, E, H	
4413	SCHOENOCAULON OFFICINALE	A, H	The maximum recommended daily dose must contain no more than the equivalent of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1mg of the dry herbal material.
4414	SCLAREOL	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4415	SCLAREOLIDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4416	SCLERANTHUS ANNUUS	A, H	
4417	SCLEROTIUM GUM	Е	Only for use in topical medicines for dermal application.
4418	SCOPOLIA CARNIOLICA	А, Н	The concentration of equivalent dry Scopolia carniolica in the medicine must be no more than 10mg/Kg or

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			10mg/L or 0.001%.
4419	SCROPHULARIA NINGPOENSIS	A, H	
4420	SCROPHULARIA NODOSA	A, H	
4421	SCURRULA PARASITICA VAR. GRACILIFLORA	A, H	
4422	SCUTELLARIA BAICALENSIS	A, E, H	
4423	SCUTELLARIA BARBATA	A, H	
4424	SCUTELLARIA LATERIFLORA	A, E, H	
4425	SEA WHIP EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.02%.
4426	SEC BUTYL 3-METHYLBUT-2-ENETHIOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4427	SEC-BUTYL THIOISOVALERATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4428	SECALE CEREALE	A, H	Gluten is a mandatory component of Secale cereale when the plant part is seed and the route of administration is other than topical and mucosal.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).
4429	SEDUM ACRE	A, H	
4430	SELAGINELLA TAMARISCINA	A, H	
4431	SELENICEREUS GRANDIFLORUS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4432	SELENIUM	H	Only for use as an active homoeopathic ingredient.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses.  A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
4433	SELENOCYSTEINE	A	Selenium is a mandatory component of Selenocysteine for oral and sublingual use.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contains selenium which is toxic in high doses.  A daily dose of 150 mcg for adults of selenium from dietary supplements should not be exceeded.'
4434	SELENOMETHIONINE	A	Selenium is a mandatory component of Selenomethionine for oral and sublingual use.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micograms for adults of selenium from dietary supplements should not be exceeded.'
4435	SELF-EMULSIFYING GLYCERYL MONOSTEARATE	Е	
4436	SEMECARPUS ANACARDIUM	A, H	When the plant part is other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			than seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
4437	SEMOLINA	E	
4438	SEMPERVIVUM TECTORUM	A, H	
4439	SENEGA ROOT DRY	A, H	
4440	SENEGA ROOT POWDER	A, H	
4441	SENNA ALEXANDRINA	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna alexandrina.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems'; and  - (LAX3) 'Do not use when

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4442	SENNA FRUIT ALEXANDRIAN DRY	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian dry.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems'; and

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4443	SENNA FRUIT ALEXANDRIAN POWDER	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian powder.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems';

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			and  - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).  When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:  - (LAX1) 'Drink plenty of water' (or words to that effect).  When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4444	SENNA FRUIT TINNEVELLY DRY	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly dry.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4445	SENNA FRUIT TINNEVELLY POWDER	A, H	When for oral or sublingual, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly powder.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4446	SENNA LEAF DRY	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna leaf dry.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]';
			- (LAX4) 'This product may

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4447	SENNA LEAF POWDER	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna Leaf Powder.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may
			cause serious bowel problems'.
4448	SENNA OCCIDENTALIS	A, H	Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna occidentalis when the route of administration is oral administration.  When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			derivatives the medicine requires the following warning statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended';
			- (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' [or words to that effect].
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contains [name of the herb(s) or the chemical component(s)]'; and  - (LAX4) 'This product may have laxative effect'.  When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended;  - (LAX1) 'Drink plenty of water' [or words to that effect]; and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4449	SENNA TORA	A, H	When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna tora.  When used in oral medicines, if the maximum recommended daily dose contains more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not
			recommended';  - (LAX2) 'Prolonged use may cause serious bowel problems'; and
			- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' (or words to that effect).
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:  - (CHILD3) 'Use in children under 12 years is not recommended';  - (LAX1) 'Drink plenty of water' (or words to that effect); and  - (LAX2) 'Prolonged use may cause serious bowel problems'.
4450	SEPIA	Н	Only for use as an active
			homoeopathic ingredient.
4451	SEQUOIA SEMPERVIRENS	A, H	
4452	SEQUOIADENDRON	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	GIGANTEUM		
4453	SERENOA REPENS	A, H	
4454	SERINE	A, E	
4455	SERUM ANGUILLAE	Н	Only for use as an active homoeopathic ingredient.
4456	SESAME OIL	A, E, H	
4457	SESAME SEED	Е	
4458	SESAMUM INDICUM	A, E, H	
4459	SETARIA ITALICA	A, H	
4460	SHARK CALCIUM CHONDROITIN SULFATE	A	
4461	SHARK CARTILAGE	A, E	The medicine requires the following warning statement on the medicine label:  - (SHARK) 'Children, pregnant or breastfeeding women, and those who have recently had a heart attack, surgery or a major accident should not consume this product without medical advice' (or words to that effect)
4462	SHARK CHONDROITIN SULFATE	A	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4463	SHARK POTASSIUM CHONDROITIN SULFATE	A	
4464	SHARK SODIUM CHONDROITIN SULFATE	A	
4465	SHARK-LIVER OIL	A, E	Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.  When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.  When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.  When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.  When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:  - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use.
			- (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.
			- (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4466	SHEA BUTTER	E	
4467	SHEA BUTTER UNSAPONIFIABLES	Е	Only for use in topical medicines for dermal application.
4468	SHELLAC	Е	
4469	SHEPHERD'S PURSE HERB DRY	A, H	
4470	SHEPHERD'S PURSE HERB POWDER	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4471	SHERRY WINE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4472	SIGESBECKIA ORIENTALIS	A, E, H	
4473	SILICA	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4474	SILICA DIMETHYL SILYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.
4475	SILICA SILYLATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
4476	SILICIFIED MICROCRYSTALLINE CELLULOSE	E	Only for use when the route of administration is other than inhalation.
4477	SILICON DIOXIDE	A, E, H	Only for use when the route of administration is other than inhalation.
4478	SILICONE QUATERNIUM-8	E	Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2.5%.  The medicine requires the following warning statement on the medicine label:  - (EYE) 'Avoid contact with eyes' (or words to that effect).
4479	SILVER	Н	Only for use as an active homoeopathic ingredient.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
4480	SILVER BEET	E, H	
4481	SILVER BOROSILICATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine should be no more than 0.6%.  Silver is a mandatory component of Silver borosilicate when the route of administration is topical.  The concentration of silver in the medicine must be no more than 1%.
4482	SILVER NITRATE	Н	Only for use as an active homoeopathic ingredient.
4483	SILYBUM MARIANUM	A, E, H	
4484	SIMABA CEDRON	A, H	
4485	SIMETHICONE	Е	
4486	SIMMONDSIA CHINENSIS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4487	SINAPIS ALBA	A, H	Allyl isothiocyanate is a mandatory component of Sinapis alba when the plant part is seed.  The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
4488	SINAPIS ARVENSIS	A, H	
4489	SINOMENIUM ACUTUM	A, H	
4490	SIPHONESTEGIA CHINENSIS	A, H	
4491	SIRAITIA GROSVENORII	A, E, H	
4492	SISYMBRIUM OFFICINALE	A, H	
4493	SKATOLE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4494	SKIPJACK-LIVER OIL	A, E	Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.
			When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.
			When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.
			When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.
			When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:
			- (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			directions for use.  - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use.  - (VITA3) 'The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
4495	SLIPPERY ELM BARK DRY	A, H	
4496	SLIPPERY ELM BARK POWDER	A, E, H	
4497	SMILAX ARISTOLOCHIIFOLIA	A, H	
4498	SMILAX CHINA	A, H	
4499	SMILAX GLABRA	A, H	
4500	SMILAX OFFICINALIS	A, E, H	
4501	SMILAX ORNATA	A, E, H	
4502	SMOKE EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
4503	SODIUM ACETATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4504	SODIUM ACETYLATED HYALURONATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.
4505	SODIUM ACID CITRATE	A, E, H	When used as an active ingredient, only for use in oral medicines.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When used as an active, only for use in oral medicines.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4506	SODIUM ACRYLATES COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.8%.
4507	SODIUM ACRYLATES CROSSPOLYMER-2	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 0.7 % (w/w).
4508	SODIUM ACRYLOYDIMETHYLTAURATE/ VP CROSSPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 2% (w/w).
4509	SODIUM ALGINATE	Е	
4510	SODIUM ASCORBATE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4511	SODIUM ASCORBYL	Е	Only for use in topical

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	PHOSPHATE		medicines for dermal application and not to be included in medicines intended for use in the eye.
			When used in a sunscreen, the concentration in the medicine must be no more than 0.1%.
			When used in products other than sunscreens, the concentration in the medicine must be no more than 0.5%.
4512	SODIUM ASCORBYL/CHOLESTERYL PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4513	SODIUM BENZOATE	E	Medicines containing benzoates require the following warning statement on the medicine label:
			- (TBNZO8) 'Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			used]' (or words to this effect) if product contains one benzoate source.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4514	SODIUM BETA-HYDROXY- BETA-METHYLBUTYRATE	A, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4515	SODIUM BETA-HYDROXY- BETA-METHYLBUTYRATE MONOHYDRATE	A, H	
4516	SODIUM BICARBONATE	A, E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'  When used as an active ingredient, the medicine may only be for oral rehydration salts in powdered and effervescent tablet dosage forms.  Medicines for use as oral rehydration therapy are subject to the following conditions:  a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;  b) the sodium content and total
			osmolarity of the solution after

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Childrens Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation 18 July 2001.'  c) the medicine requires the
			following warning statements on the medicine label:  - (UOAD) 'Use only as directed.'
			- (DIAR) 'If diarrhoea persists for more than 6 hours in infants under 6 months - 12 hours in children under 3 years - 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice (or words to that effect).'
			- (DIAR3) 'If diarrhoea persists, seek medical advice.'
4517	SODIUM BISULFITE	Е	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			Medicines containing sulfites salts require the following warning statement on the medicine label:
			- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
4518	SODIUM BROMIDE	Н	Only for use as an active homoeopathic ingredient.
4519	SODIUM C14-16 OLEFIN SULFONATE	E	Only for use in topical medicines for dermal application.
4520	SODIUM CARBOMER	E	Only for use as an excipient in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
4521	SODIUM CARBONATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4522	SODIUM CARBONATE MONOHYDRATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4523	SODIUM CARBOXYMETHYL BETAGLUCAN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.005%.
4524	SODIUM CARRAGEENAN	Е	
4525	SODIUM CASEINATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4526	SODIUM CETOSTEARYL SULFATE	Е	Only for use in topical medicines for dermal application.
4527	SODIUM CHLORIDE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4528	SODIUM CHONDROITIN SULFATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 0.001%.
4529	SODIUM CITRATE	A, E	Only for oral use when used as an active ingredient.
			When for oral or sublingual use and the total amount of sodium

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4530	SODIUM CITRATE DIHYDRATE	A, E	Only for oral use when used as an active ingredient.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4531	SODIUM COCO PG-DIMONIUM CHLORIDE PHOSPHATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 0.05%.
4532	SODIUM COCOAMPHOACETATE	Е	Only for use in topical medicines for dermal application.
4533	SODIUM COCOYL SARCOSINATE	Е	Only for use in topical medicines for dermal application.
4534	SODIUM CYCLAMATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4535	SODIUM DEHYDROACETATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
4536	SODIUM DNA	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
4537	SODIUM DODECYLBENZENESULFONAT E	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 30%.
4538	SODIUM ERYTHORBATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			(or words to that effect).
4539	SODIUM ETHYL HYDROXYBENZOATE	E	
4540	SODIUM FLUORIDE	A, E, H	Fluoride is a mandatory component of Sodium fluoride.  Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene.  When used as an active ingredient, it is subject to the following conditions:  a) Only for use in combination with at least one other listable therapeutically active ingredient.  b) The concentration of fluoride ion must be no more than 1,500 mg/kg.  When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:  - (DNTSW) 'Do not swallow.'  - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			less.'  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4541	SODIUM FUMARATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4542	SODIUM GLYCEROPHOSPHATE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4543	SODIUM HYALURONATE	Е	Only for use in topical medicines for dermal application.
4544	SODIUM HYDROGENATED TALLOW GLUTAMATE	E	Only for use in topical medicines for dermal application.
4545	SODIUM HYDROXIDE	E	The concentration in the medicine must be no more than 5%.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).  When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
4546	SODIUM HYDROXYCITRATE	A	
4547	SODIUM HYDROXYETHYL ACRYLATE/ACRYLOYLDIMETH YL TAURATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.
4548	SODIUM HYDROXYMETHYLGLYCINATE	E	Only for use in topical medicines for dermal application.
4549	SODIUM HYPOCHLORITE	Е	Chlorine is a mandatory component of Sodium

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			hypochlorite.  The concentration of chlorine in the medicine must be no more than 4%.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4550	SODIUM ISOSTEAROYL LACTYLATE	Е	Only for use in topical medicines for dermal application.
4551	SODIUM LACTATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4552	SODIUM LAURETH SULFATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4553	SODIUM LAUROAMPHOACETATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4554	SODIUM LAUROYL METHYL ISETHIONATE	Е	Only for use in wash-off topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 11%.
4555	SODIUM LAUROYL SARCOSINATE	Е	Only for use in topical medicines for dermal application.
4556	SODIUM LAURYL PHOSPHATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4557	SODIUM LAURYL SULFATE	Е	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4558	SODIUM LAURYL SULFOACETATE	Е	Only for use in topical medicines for dermal application.
4559	SODIUM MAGNESIUM SILICATE	Е	Only for use in topical medicines for dermal application.
4560	SODIUM MANNOSE PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.5%.
4561	SODIUM METABISULFITE	Е	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
			Medicines containing sulfites salts require the following warning statement on the medicine label:
			- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
4562	SODIUM METAPHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.
			The concentration in the medicine must not be more than 0.1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4563	SODIUM METHYL COCOYL TAURATE	Е	Only for dental use.  The concentration in the medicine must be no more than 2%.
4564	SODIUM METHYL HYDROXYBENZOATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).  Medicines containing hydroxybenzoates require the following warning statement on the medicine label:  - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4565	SODIUM MOLYBDATE DIHYDRATE	A	Only for use in oral medicines.  Molybdenum is a mandatory component of Sodium molybdate dihydrate.  The percentage of molybdenum from sodium molybdate dihydrate should be calculated based on the molecular weight of sodium molybdate dihydrate.  The maximum daily dose of molybdenum from Sodium molybdate dihydrate must be no more than 125 micrograms.
4566	SODIUM MONOFLUOROPHOSPHATE	A	Fluoride is a mandatory component of sodium monofluorophosphate.  Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene.  When used as an active ingredient, it is subject to the following conditions:  a) Only for use in combination with at least one other listable therapeutically active ingredient.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			b) The concentration of fluoride ion must be no more than 1,500 mg/kg.  When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires
			mg/kg, the medicine requires the following statements on the medicine label: - (DNTSW) 'Do not swallow.' - (CHILD4) 'Do not use [this
			product/insert name of product] in children 6 years of age or less.'  When for oral or sublingual use
			and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'
4567	SODIUM MYRISTOYL GLUTAMATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 0.0164%.
4568	SODIUM NITRATE	Н	Only for use as an active homoeopathic ingredient.
4569	SODIUM NONOXYNOL-4 SULFATE	Е	Only for use in topical medicines for dermal application.
4570	SODIUM PANTOTHENATE	A, E, H	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4571	SODIUM PCA	E	Only for use in topical medicines for dermal application.

ingredient in the medicine  A, H  Boron is a mandatory component of sodium perborate.  When for internal use, the maximum recommended dose must not provide mor than 6 mg of boron.  When used preparations for dermal use, which are not in paediatric or antifungal use concentration of boron from ingredients in the product in not exceed 3500 mg/kg or mg/L or 0.35%.  When for oral or sublingua and the total amount of soo from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following war statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [stat quantity and units] of sodium perborate.	Column 1	Column 2	Column 3	Column 4
component of sodium perborate.  When for internal use, the maximum recommended d dose must not provide mor than 6 mg of boron.  When used preparations for dermal use, which are not a paediatric or antifungal use concentration of boron from ingredients in the product a not exceed 3500 mg/kg or mg/L or 0.35%.  When for oral or sublingua and the total amount of soot from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warn statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [stat quantity and units] of sodium personal materials.		Ingredient Name	ingredient in	Specific requirements(s) applying to the ingredient in Column 2
component of sodium perborate.  When for internal use, the maximum recommended d dose must not provide mor than 6 mg of boron.  When used preparations for dermal use, which are not a paediatric or antifungal use concentration of boron from ingredients in the product a not exceed 3500 mg/kg or mg/L or 0.35%.  When for oral or sublingua and the total amount of soot from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warn statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [stat quantity and units] of sodium personal materials.				
(or words to that effect).'	4572	SODIUM PERBORATE	A, H	component of sodium perborate.  When for internal use, the maximum recommended daily dose must not provide more than 6 mg of boron.  When used preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron from all ingredients in the product must not exceed 3500 mg/kg or 3500 mg/L or 0.35%.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
4573 SODIUM PERCARBONATE E Only for use in topical medicines for dermal	4573	SODIUM PERCARBONATE	E	_

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.  The concentration in the medicine must be no more than 15%.
4574	SODIUM POLYACRYLATE	Е	Only for use in topical medicines for dermal application.
4575	SODIUM POLYACRYLATE STARCH	E	Only to be used in a medicine where Procter & Gamble Australia Pty Ltd (Client ID 11364), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 27 September 2020.  Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must not be more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4576	SODIUM POLYMETAPHOSPHATE	Е	
4577	SODIUM PROPIONATE	Е	Only for use in topical medicines for dermal application.
4578	SODIUM PROPYL HYDROXYBENZOATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).  Medicines containing hydroxybenzoates require the following warning statement on the medicine label:  - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect)

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			if product contains one hydroxybenzoate source.
4579	SODIUM RNA	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.2%.
4580	SODIUM SELENATE	A, H	Selenium is a mandatory component of sodium selenate.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4581	SODIUM SELENATE DECAHYDRATE	A	Selenium is a mandatory component of sodium selenate decahydrate.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily
			dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
4582	SODIUM SELENITE	A, H	Selenium is a mandatory component of Sodium selenite.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the
			medicine requires the following warning statement

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
4583	SODIUM SELENITE PENTAHYDRATE	A	Selenium is a mandatory component of Sodium selenite pentahydrate.  Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.  When for oral use, the medicine requires the following warning statement on the medicine label:  - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4584	SODIUM SILICATE	Е	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.
			When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.
			When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4585	SODIUM STARCH GLYCOLLATE	Е	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:
			- (SODIUM) 'The recommended daily dose of this medicine contains [state

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			quantity and units] of sodium' (or words to that effect).
4586	SODIUM STARCH GLYCOLLATE TYPE A	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4587	SODIUM STEARATE	Е	Only for use in topical medicines for dermal application.
4588	SODIUM STEAROXY PG- HYDROXYETHYLCELLULOSE SULFONATE	E	Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4589	SODIUM STEAROYL GLUTAMATE	E	Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 2.5%.
4590	SODIUM STEAROYL LACTYLATE	E	Only for use in topical medicines for dermal application.
4591	SODIUM STEARYL PHTHALAMATE	E	Only for use in medicines for dermal application and not to be used in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.
4592	SODIUM SUCCINATE	E	Only for use in topical medicines for dermal application.
4593	SODIUM SULFATE	A, E, H	When it is not intended to be a laxative, the medicine requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label:  - (LAX4) 'Substance may have a laxative effect'.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4594	SODIUM SULFATE DECAHYDRATE	A, E, H	When it is not intended to be a laxative, the medicine requires the following warning statement on the medicine label:  - (LAX4) 'Substance may have a laxative effect'.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4595	SODIUM SULFITE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).  Medicines containing sulfites salts require the following warning statement on the medicine label:  - (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4596	SODIUM SULFITE HEPTAHYDRATE	E	Only for use in topical medicines for dermal application.  Medicines containing sulfites salts require the following warning statement on the medicine label:  - (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
4597	SODIUM TRIPOLYPHOSPHATE	E	Only for use when the route of administration is topical for dermal application, mucous membrane (buccal mucosa) or dental.  Not to be included in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4598	SOLANUM DULCAMARA	A, H	When for internal use, steroidal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			alkaloids calculated as solanine is a mandatory component of Solanum dulcamara.  When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as
			solanine.
4599	SOLANUM FEROX	A, H	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum ferox.  When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4600	SOLANUM LYCOCARPUM FRUIT EXTRACT	E	Only for use in topical medicines for dermal use and not to be included in topical medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.02%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4601	SOLANUM MELONGENA	A, H	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum melongena.  When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4602	SOLANUM NIGRUM	A, H	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum nigrum.  When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.
4603	SOLANUM TUBEROSUM	A, H	When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum tuberosum.  When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			solanine.
4604	SOLIDAGO GIGANTEA	A, H	
4605	SOLIDAGO GIGANTEA MIS	A, E, H	
4606	SOLIDAGO VIRGAUREA	A, E, H	
4607	SOLUBLE MAIZE STARCH	E	
4608	SOLUBLE POTATO STARCH	E	
4609	SOLVENT GREEN 3	E	Permitted for use only as a colour for topical use.
4610	SOLVENT RED 1	E	Permitted for use only as a colour for topical use.
4611	SOLVENT VIOLET 13	E	Permitted for use only as a colour for topical use.
4612	SOLVENT YELLOW 172	E	Permitted for use only as a colour for topical use.  The concentration in the medicine must be no more than 0.3%.
4613	SOLVENT YELLOW 33	E	Permitted for use only as a colour for topical use.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4614	SOPHORA FLAVESCENS	A, E, H	
4615	SOPHORA TONKINENSIS	A, H	
4616	SORBIC ACID	E	The medicine requires the following warning statement on the medicine label:  - (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.
4617	SORBITAN ISOSTEARATE	E	Only for use in topical medicines for dermal application.
4618	SORBITAN MONO-OLEATE	Е	
4619	SORBITAN MONOLAURATE	E	
4620	SORBITAN MONOSTEARATE	E	
4621	SORBITAN OLEATE	E	
4622	SORBITAN OLIVATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 10%.
4623	SORBITAN PALMITATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 2%.
4624	SORBITAN SESQUIISOSTEARATE	E	Only for use in topical medicines for dermal application.
4625	SORBITAN SESQUIOLEATE	E	Only for use in topical medicines for dermal application.
4626	SORBITAN STEARATE	E	
4627	SORBITAN TRISTEARATE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4628	SORBITOL	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.  When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:  - (SUGOLS) 'Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea' (or words to that effect).
4629	SORBITOL SOLUTION (70 PER CENT) (CRYSTALLISING)	A, E	Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (crystallising).
			When used as an active ingredient, can only be supplied as an uncompounded

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
			When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:  - (SUGOLS) 'Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea (or words to that effect).'
4620	CORDITOL COLLITION (70 DED	A.F.	
4630	SORBITOL SOLUTION (70 PER CENT) (NON-CRYSTALLISING)	A, E	Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (non-crystallising).
			When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
			When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:  - (SUGOLS) 'Products containing [insert name of sugar alcohol(s)] may have a
			laxative effect or cause diarrhoea (or words to that effect).'
4631	SORBUS AUCUPARIA	A, H	
4632	SORBUS DOMESTICA	A, H	
4633	SORGHUM	Е	
4634	SORGHUM VULGARE	A, H	
4635	SOY PHOSPHATIDYLSERINE- ENRICHED SOY LECITHIN LIQUID	A	Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin liquid.  The concentration of soy

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			phosphatidylserine in the medicine must be no more than 15%.
4636	SOY PHOSPHATIDYLSERINE- ENRICHED SOY LECITHIN POWDER	A	Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin powder.  The concentration of soy phosphatidylserine in the medicine must be no more than 15%.
4637	SOY POLYSACCHARIDE	E	
4638	SOY PROTEIN	Е	
4639	SOY STEROL	Е	
4640	SOYA BEAN	Е	
4641	SOYA BRAN	E	
4642	SOYA OIL	A, E, H	
4643	SOYBEAN FLOUR	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4644	SOYBEAN GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.
4645	SPARGANIUM STOLONIFERUM	A, H	
4646	SPARTIUM JUNCEUM	A, H	
4647	SPATHOLOBUS SUBERECTUS	A, H	
4648	SPEARMINT OIL	A, E, H	When the ingredient is included in a medicine that is listed in the Register:  - on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);  - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or  - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			a) Menthol is a mandatory component of spearmint oil.
			b) When the medicine is for topical use:
			(i) the medicine must not be intended for use in the eye or on damaged skin;
			(ii) the maximum concentration of menthol must not exceed 5%; and
			(iii) the following warning statements are required on the medicine label:
			- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develops, discontinue use; and
			- (EYE) Avoid contact with eyes (or words to that effect).
			c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
4649	SPEARMINT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
			Menthol is a mandatory component of spearmint oil terpeneless.
			When the medicine is for topical use:
			a) the medicine must not be intended for use in the eye or on damaged skin;
			b) the maximum concentration of menthol must not exceed 5%; and
			c) the medicine requires the following warning statements on the medicine label:
			- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;
			- (IRRIT) If irritation develops, discontinue use; and
			- (EYE) Avoid contact with

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			eyes (or words to that effect).  When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.
4650	SPHINGOLIPIDS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
4651	SPIGELIA ANTHELMIA	A, H	
4652	SPIGELIA MARILANDICA	A, H	The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.
4653	SPIKE LAVENDER OIL	A, E, H	Camphor is a mandatory component of spike lavender oil.  In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.
			In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect); and  - (NTAKEN) 'Not to be taken'.  In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert
			fitted on the container and include the following warning statements on the medicine label:
			- (CHILD) 'Keep out of reach of children' (or words to that effect); and

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (NTAKEN) 'Not to be taken'.  In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect); and  - (NTAKEN) 'Not to be taken'.  If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.
4654	SPINACH	Е	
4655	SPINACIA OLERACEA	A, E, H	
4656	SPIRODELA POLYRRHIZA	A, H	
4657	SPIRULINA	Е	
4658	SPRAY-DRIED GLUCOSE SYRUP	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4659	SPRAY-DRIED LIQUID GLUCOSE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4660	SPRUCE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4661	SQUALANE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4662	SQUALENE	A, E	
4663	SQUID OIL	A	Only for use in oral medicines.  The medicine requires the following warning statement on the medicine label:  - (SFOOD) 'Derived from seafood'.  Must be obtained from species of the order Teuthida of the class Cephalopoda, be used in combination with other ingredients in the medicine and be presented in a therapeutic dosage form for therapeutic use.
4664	SQUILL DRY	A, H	
4665	SQUILL INDIAN DRY	A, H	
4666	SQUILL INDIAN POWDER	А, Н	
4667	SQUILL POWDER	А, Н	
4668	ST JOHN'S WORT DRY EXTRACT QUANTIFIED	A	When used for oral ingestion, the medicine requires the following warning statement on the medicine label:  - (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Consult your doctor.'
4669	ST JOHN'S WORT HERB DRY	A, H	When used for oral ingestion, the medicine requires the following warning statement on the medicine label:  - (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'
4670	ST JOHN'S WORT HERB POWDER	A, H	When used for oral ingestion, the medicine requires the following warning statement on the medicine label:  - (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'
4671	STACHYS OFFICINALIS	A, E, H	
4672	STACHYS PALUSTRIS	A, H	
4673	STACHYURUS HIMALAICUS	A, H	
4674	STANNIC OXIDE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 0.005%.
4675	STANNOUS CHLORIDE	Н	Only for use as an active homoeopathic ingredient.
4676	STAR ANISE OIL	A, E	When the concentration in the medicine is more than 50% and the nominal capacity of the container is equal to or less than 50mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect).
4677	STARCH	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4.650			
4678	STARCH SODIUM OCTENYL SUCCINATE	E	
4679	STEARALKONIUM CHLORIDE	Е	Only for use in topical medicines for dermal application.
4680	STEARALKONIUM HECTORITE	E	Only for use in topical medicines for dermal application.
4681	STEARAMIDE	E	Only for use in topical medicines for dermal application.
4682	STEARAMIDOETHYL DIETHYLAMINE	E	Only for use in topical medicines for dermal application.
4683	STEARAMIDOPROPYL DIMETHYLAMINE	E	Only for use in topical medicines for dermal application.
4684	STEARAMIDOPROPYL PG- DIMONIUM CHLORIDE PHOSPHATE	E	Only for use in topical medicines for dermal application.  The concentration in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 2%.
			When the medicine is intended to be used on the eye, the medicine requires the following warning statement on the medicine label:
			- (EYE2) 'May be irritant to the eyes' (or words to that effect).
4685	STEARETH-10	E	Only for use in topical medicines for dermal application.
4686	STEARETH-100	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1.5%.
4687	STEARETH-2	E	Only for use in topical medicines for dermal application.
4688	STEARETH-20	E	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
4689	STEARETH-21	Е	Only for use in topical medicines for dermal application.
4690	STEARETH-5	E	Only for use in topical medicines for dermal application.
4691	STEARIC ACID	Е	
4692	STEAROPTENES	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4693	STEAROXY DIMETHICONE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4694	STEAROXYTRIMETHYLSILANE	Е	Only for use in topical medicines for dermal application.
4695	STEAROYL MACROGOLGLYCERIDES	E	Only for use in oral medicines.  The concentration in the medicine must be no more than 0.6%.
4696	STEARYL ACETATE	E	Only for use in topical medicines for dermal application.
4697	STEARYL ALCOHOL	E	
4698	STEARYL DIMETHICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 4.5%.  The medicine requires the following warning statements on the medicine label:
			- (EYE2) 'May be irritant to the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			eyes' (or words to that effect)  - (EYE) 'Avoid contact with eyes' (or words to that effect).
4699	STEARYL GLYCYRRHETINATE	Е	Only for use in topical medicines for dermal application.
4700	STEARYL HEPTANOATE	Е	Only for use in topical medicines for dermal application.
4701	STEARYL MYRISTATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4702	STEARYL STEARATE	Е	Only for use in topical medicines for dermal application.
4703	STELLARIA CHAMAEJASME	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4704	STELLARIA DICHOTOMA	A, H	
4705	STELLARIA MEDIA	A, E, H	
4706	STEMONA JAPONICA	A, H	
4707	STEMONA SESSILIFOLIA	A, H	
4708	STENOTAPHRUM SECUNDATUM	A, H	
4709	STEPHANIA TETRANDA	A, H	
4710	STERCULIA	A, H	
4711	STERCULIA TRAGACANTHA	A, H	
4712	STERCULIA URENS	A, H	
4713	STEVIA REBAUDIANA	A, E, H	
4714	STEVIOL GLYCOSIDES	E	Only for use in oral medicines.
4715	STILLINGIA SYLVATICA	A, H	
4716	STORAX PREPARED	A, E, H	
4717	STRAWBERRY	Е	
4718	STRAWBERRY ESSENCE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4719	STREPTOCOCCUS SALIVARIUS	A	Permitted for use in only oral medicines and only when the strain of Streptococcus salivarius is confirmed to be K12.  The name of strain must be declared on the label.  The following warning statement is required on the medicine label:  - (CHILD5) 'Use in children under 3 years is not recommended'.
4720	STREPTOCOCCUS THERMOPHILUS	A	
4721	STROBILANTHES CUSIA	A, H	
4722	STRONG AMMONIA SOLUTION	Е	Ammonia is a mandatory component of dilute ammonia solution.  The concentration of ammonia in the medicine must be no more than 0.5%.  When for internal use, the concentration in the medicine must be no more than 0.25%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4723	STRONTIUM CARBONATE	Н	Only for use as an active homoeopathic ingredient.
4724	STROPHANTHUS GRATUS	Н	Only for use as an active homoeopathic ingredient.
4725	STROPHANTHUS HISPIDUS	Н	Only for use as an active homoeopathic ingredient.
4726	STRYCHNOS IGNATII	Н	Only for use as an active homoeopathic ingredient.  Strychnine (of Strychnos spp.) is a mandatory component of Strychnos ignatii.  The concentration of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.
4727	STRYCHNOS NUX-VOMICA	A, H	Strychnine (of Strychnos spp.) is a mandatory component of Strychnos nux-vomica.  The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4728	STYPHNOLOBIUM JAPONICUM	A, E, H	
4729	STYRAX BENZOIN	A, E, H	
4730	STYRAX OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a
4731	STYRAX PARALLELONEURUM	А, Н	medicine must be no more 1%.
4732	STYRAX TONKINENSIS	A, H	
4733	STYRENE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4734	STYRENE/ACRYLATES	E	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	COPOLYMER		application.
4735	STYROLYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4736	SUBLIMED SULFUR	Н	Only for use as an active homoeopathic ingredient.
4737	SUCCINIC ACID	Е	
4738	SUCRALOSE	Е	
4739	SUCROSE	E	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			'Contains sugars' (or words to that effect) if medicine contains two or more sugars.  If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:  - (LACT) 'Contains lactose' (or words to that effect).
4740	SUCROSE ACETATE ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4741	SUCROSE ACETATE PALMITATE STEARATE	E	Only for use in topical medicines for dermal application and not intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 0.3%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4742	SUCROSE COCOATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 2%.
4743	SUCROSE DISTEARATE	Е	Only for use in topical medicines for dermal application.
4744	SUCROSE LAURATE	E	When for oral or sublingual use, Sucrose is a mandatory component of Sucrose laurate.  When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contains two or more sugars.  If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:  - (LACT) 'Contains lactose' (or words to that effect).
4745	SUCROSE OCTAACETATE	E	When for oral or sublingual use, sucrose is a mandatory component of sucrose octaacetate.  When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.  If one of the sugars is lactose then the medicine also requires

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
4746	SUCROSE PALMITATE	E	Only for use in topical medicines for dermal application.
4747	SUCROSE POLYCOTTONSEEDATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.  The medicine requires the following warning statements on the medicine label:  - (EYE) 'Avoid contact with the eyes' (or words to that effect)  - (EYE2) 'May be irritant to the eyes' (or words to that effect).
4748	SUCROSE STEARATE	E	For use in topical medicines for dermal application and not to

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			be included in medicines intended for use in the eye.  When for topical use, the concentration in the medicine must be no more than 0.25%.  For oral use as a manufacturing aid only.  When for oral use, the concentration in the medicine must be no more than 0.2 mg per dosage unit.
4749	SUCROSE TRISTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 2%.
4750	SUDAN III	Е	Permitted for use only as a colour for topical use.
4751	SUGAR CANE WAX ALCOHOLS	А, Н	The maximum recommended daily dose must not provide more than 12mg.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The medicine requires the following warning statements on the medicine label:  - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
4752	SUGARCANE	E, H	When for oral or sublingual use, sucrose is a mandatory component of Sugarcane.  When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.  If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label: - (LACT) 'Contains lactose' (or words to that effect).
4753	SULFATED CASTOR OIL	E	Only for use in topical medicines for dermal application.
4754	SULFATED LOW MOLECULAR WEIGHT FUCANS	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.025%.
4755	SULFUR DIOXIDE	E	Medicines containing sulfites salts require the following warning statement on the medicine label:  - (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4756	SULFUR IODIDE	Н	Only for use as an active homoeopathic ingredient.
4757	SULFURIC ACID	E, H	Only for use as an active homoeopathic ingredient or excipient ingredient.  The concentration in the medicine must be no more than 0.5%.
4758	SULFURISED 1-METHYL-4-(1-METHYLETHENYL)-CYCLOHEXENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4759	SULISOBENZONE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 10%.  When used in primary

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4760	SULISOBENZONE SODIUM	A	Only for use as an active ingredient in sunscreens for dermal application and not to

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 10%.
			When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			when exposed to the sun' (or words to this effect).
4761	SUNFLOWER OIL	A, E, H	
4762	SUNFLOWER SEED	E, H	
4763	SUNSET YELLOW FCF	Е	Permitted for use only as a colour for either topical use or with an oral route of administration.
4764	SUNSET YELLOW FCF ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
4765	SUPEROXIDE DISMUTASE	E	Only for use in topical medicines for dermal application.
4766	SWEDE	Е	
4767	SWEET ORANGE OIL TERPENES AND TERPENOIDS	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4768	SWEET POTATO	E	
4769	SWERTIA CHIRATA	A, H	
4770	SWIETENIA MAHOGANI	A, H	
4771	SYAGRUS ROMANZOFFIANA	A, E, H	
4772	SYMPHYTUM OFFICINALE	Н	When used orally as an active homoeopathic ingredient, the concentration must be a dilution of 12X or more.  When used in topical medicines for dermal application, the concentration in the preparation must be no more than 10mg/kg or 10mg/L or 0.001%.
4773	SYMPLOCARPUS FOETIDUS	A, H	
4774	SYNTHETIC BEESWAX	E	Only for use in topical medicines for dermal applications.
4775	SYNTHETIC TERPENE RESIN	E	Only for use in topical, oral or

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			oral application medicines.  When the route of administration is oral, the dosage form must be chewing gum.
4776	SYNTHETIC WAX	Е	
4777	SYRINGA RETICULATA	A, H	
4778	SYRINGA VULGARIS	A, H	
4779	SYZYGIUM AROMATICUM	A, E, H	When the plant preparation is oil or distillate and the concentration of this oil or distillate in the product is greater than 25%, the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'.  When the plant preparation is oil or distillate, the concentration of this oil or distillate in the medicine is greater than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, a child

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			resistant closure and restricted flow insert must be fitted on the container.
			When the plant preparation is oil or distillate, the concentration of oil or distillate in the product is greater than 25% and the nominal capacity of the container is less than 15 millilitres, a restricted flow insert must be fitted on the container.
			When the plant preparation is oil or distillate and the preparation is for topical use in the mouth, the preparation may not contain more than 5 millilitres of the oil or distillate and the concentration of oil or distillate in the product must not be greater than 25%.
4780	SYZYGIUM CUMINI	A, H	
4781	SYZYGIUM JAMBOS	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must not be more than 0.0693%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4782	TABEBUIA SERRATIFOLIA	A, E, H	
4783	TAGETES ERECTA	A, H	
4784	TAGETES MINUTA	A, E, H	
4785	TAGETES OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4786	TAIPAN SNAKE	H	Only for use as an active homoeopathic ingredient.
4787	TALLOW	E	Only for use in topical medicines for dermal application.
4788	TALLOW GLYCERIDES	E	
4789	TAMARINDUS INDICA	E	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4790	TAMARIX APHYLLA	A, H	
4791	TAMARIX CHINENSIS	A, H	
4792	TAMARIX GALLICA	A, H	
4793	TAMUS COMMUNIS	А, Н	If the plant part is fruit or root, the maximum recommended daily dose must be no more than 1 mg of the equivalent dry fruit or dry root of Tamus communis.
4794	TANACETUM CINERARIIFOLIUM	A, H	The concentration in the medicine must be no more than 10%.
4795	TANACETUM PARTHENIUM	A, E, H	
4796	TANACETUM VULGARE	A, H	Oil (of Tanacetum vulgare) is a mandatory component of Tanacetum vulgare.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration of oil (of Tanacetum vulgare) in the medicine must be no more than 0.8%.
4797	TANGERINE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4798	TANGERINE OIL COLDPRESSED	A, E, H	When used internally, oxedrine is a mandatory component of tangerine oil coldpressed.  The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.
4799	TANNIC ACID	E	
4800	TAPIOCA STARCH	Е	
4801	TARAXACUM MONGOLICUM	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4802	TARAXACUM OFFICINALE	A, E, H	
4803	TARO	Е	
4804	TARRAGON OIL	A, E, H	
4805	TARTARIC ACID	Е	
4806	TARTRAZINE	E	Permitted for use only as a colour for oral and topical use.  The medicine requires the following warning statement on the medicine label:  - (TART) 'Contains tartrazine' (or words to that effect).
4807	TARTRAZINE ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.  The medicine requires the following warning statement on the medicine label:  - (TART) 'Contains tartrazine' (or words to that effect).
4808	TASMANNIA LANCEOLATA	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
4809	TAURINE	A, E	
4810	TEA-STEARATE	Е	Only for use in topical medicines for dermal application.
4811	TERMINALIA ARJUNA	A	Only for use in oral medicines.  Only for use when the plant part is bark.  The maximum recommended daily dose must be no more than 6 grams of Terminalia arjuna dried bark or its extract equivalents.  The medicine requires the following warning statements on the medicine label:  - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)  - (CHILD2) 'Not suitable for children'.
4812	TERMINALIA BELLIRICA	A	Only for use when the preparation is as an aqueous

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			extract of the fruit pericarp.
4813	TERMINALIA CATAPPA	A, H	
4814	TERMINALIA CHEBULA	A, H	
4815	TERMINALIA FERDINANDIANA	A, E, H	Only for use when the plant part is fruit flesh, fruit flesh dry or the preparation is as an aqueous extract of the fruit flesh.  When used as an excipient, the ingredient is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.  When used as an excipient, the concentration in the medicine must be no more than 0.3%.
4816	TERMINALIA SERICEA	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  Only for use when the plant part is root bark.  Only methanol/water (90:10; V/V) extract of Terminalia sericea bark of the root is

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			approved.  The concentration in the medicine must be no more than 0.1%.
4817	TERPINEN-4-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4818	TERPINEOL	Е	
4819	TERPINEOL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4820	TERPINOLENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4821	TERPINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4822	TERPINYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.  If used as a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
4823	TERPINYL METHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4824	TERT-BUTYL ALCOHOL	E	Only for use in topical medicines for dermal application.
4825	TERT-BUTYL HYDROQUINONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4826	TERT-BUTYL METHYL ETHER	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4827	TERT-BUTYLPYRAZINE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4828	TETRACLINIS ARTICULATA	A, E, H	
4829	TETRADECYL AMINOBUTYROYLVALYLAMIN OBUTYRIC UREA TRIFLUOROACETATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 0.002%.
4830	TETRADIUM RUTICARPUM	А, Н	When for internal use, oxedrine is a mandatory component of Tetradium ruticarpum.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg.
4831	TETRAHEXYLDECYL ASCORBATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 1%.
4832	TETRAHYDRO LINALYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4833	TETRAHYDRO PARA- METHYLQUINOLINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
4834	TETRAHYDRO-6-(3-PENTENYL)- 2H-PYRAN-2-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4835	TETRAHYDRODIFERULOYLME THANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
4836	TETRAHYDROFURFURYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
4837	TETRAHYDROGERANYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4838	TETRAHYDROLINALOOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4839	TETRAHYDROMUGUOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4840	TETRAHYDROMYRCENOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a
			medicine must be no more than 1%.
4841	TETRAHYDROXYPROPYL ETHYLENEDIAMINE	Е	Only for use in topical medicines for dermal application.
4842	TETRAMETHYL ACETYLOCTAHYDRONAPHTHA LENES	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4843	TETRAPANAX PAPYRIFER	A, H	
4844	TETRASODIUM ETIDRONATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4845	TETRASODIUM PYROPHOSPHATE	E	When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4846	TEUCRIUM CHAMAEDRYS	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium chamaedrys.
4847	TEUCRIUM MARUM	A, H	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material of Teucrium marum.
4848	TEUCRIUM SCORODONIA	A, H	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material of Teucrium

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			scorodonia.
4849	THAPSIA GARGANICA	A, H	
4850	THAUMATIN	Е	
4851	THEASPIRANE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4852	THEMEDA TRIANDRA	A, H	
4853	THEOBROMA CACAO	A, E, H	Caffeine is a mandatory component of Theobroma cacao.  When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 1 mg but no more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:  - (CAFFR) 'The recommended dose of this medicine provides

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			small amounts of caffeine.'  When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:  - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
4854	THEOBROMA OIL	A, E, H	
4855	THIAMINE	A, E	
4856	THIAMINE HYDROCHLORIDE	A, E	
4857	THIAMINE NITRATE	A, E	
4858	THIOCINEOLE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4859	THIOTAURINE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.02%.
4860	THLASPI ARVENSE	A, E, H	
4861	THREONINE	A, E	
4862	THUJA OCCIDENTALIS	A, H	
4863	THUJA PLICATA	A, E, H	
4864	THYME HERB DRY	A, E, H	
4865	THYME OIL	A, E, H	When the concentration of Thyme oil in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the warning statement:  - (CHILD) 'Keep out of reach of children' (or words to that
4866	THYMOL	A, E	When used as an active ingredient, the medicine must

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			be medicated space spray or medicated throat lozenges.  When used as an excipient, only for use in topical medicines for dermal applications.
4867	THYMUS CAPITATUS	A, E, H	When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect).
4868	THYMUS GLAND	Н	Only for use as an active homoeopathic ingredient.
4869	THYMUS MASTICHINA	A, E, H	When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).
4870	THYMUS SERPYLLUM	A, E, H	When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).
4871	THYMUS VULGARIS	A, E, H	When the plant preparation is oil or distillate, the nominal capacity of the container must be no more than 25 millilitres.  When the concentration of Thymus vulgaris oil or distillate in the preparation is greater than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect)
4872	THYMUS VULGARIS MIS	A, E, H	When the plant preparation is an oil or distillate, the nominal capacity of the container must be no more than 25 millilitres.  When the concentration of Thymus vulgaris mis oil or distillate in the preparation is greated than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect)
4873	THYMUS ZYGIS	A, H	When the plant preparation is an oil or a distillate, the nominal capacity of the container must be no more than 25 millilitres.  When the concentration of Thymus zygis oil or distillate in the preparation is greater

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label:  - (CHILD) 'Keep out of reach of children' (or words to that effect).
4874	TIGER SNAKE	Н	Only for use as an active homoeopathic ingredient.
4875	TILACTASE	A	Must be derived from Aspergillus oryzae and comply with the relevant USP monograph.  When the dosage form is undivided, the units 'acid lactase units per gram' and 'Thousand acid lactase units per gram' are permitted.  When the dosage form is divided, the units 'acid lactase units' and 'thousand acid lactase units' are permitted.
4876	TILIA CORDATA	A, E, H	
4877	TILIA PLATYPHYLLOS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4878	TILIA TOMENTOSA	A, H	
4879	TILIA X VULGARIS	A, E, H	
4880	TILIANTOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4881	TIN	Н	Only for use as an active homoeopathic ingredient.
4882	TINOSPORA CORDIFOLIA	A, H	
4883	TINOSPORA SINENSIS	A, H	
4884	TITANIUM DIOXIDE	A, E	For use as an active ingredient only in sunscreens for dermal application.
			The concentration in sunscreens must be no more than 25%.
			For use as an excipient only as a colour in oral medicines and as a colour in topical medicines for dermal application.
			Not to be included in medicines intended for use in

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
		the medicine	the eye.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear
			when exposed to the sun' (or words to this effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4885	TOCOCYSTEAMIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.01%.
4886	TOCOFERSOLAN	E	Only for oral and topical use.  When for oral use, the concentration in the medicine must be no more than 10% w/w.  When used in topical medicines for dermal application, it is not to be included in medicines intended for use in the eye.  When for topical use, the concentration in the medicine must be no more than 0.1%
4887	TOCOPHEROL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4888	TOCOPHERYL GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.  The concentration in the medicine must be no more than 0.05%
4889	TOCOPHERYL LINOLEATE	E	Only for use in topical medicines for dermal application.
4890	TOCOPHERYL NICOTINATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration must not exceed 0.3%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4891	TOLU BALSAM	A, E, H	
4091	TOLU BALSAM	A, E, H	
4892	TOLUENE	Е	The residual solvent limit for toluene is 8.9 mg per maximum recommended daily dose.
			The concentration in the medicine must be no more than 0.089%.
4893	TOLYL ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a
4894	TOLYLALDEHYDE	E	medicine must be no more 1%.  Permitted for use only in
	GLYCERYLACETAL		combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
4895	TOMATO	E	
4896	TONKA	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than
4897	TONKA BEAN EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4898	TONONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more than 1%.
4899	TOXICODENDRON DIVERSILOBUM	Н	Only for use as an active homoeopathic ingredient.
4900	TOXICODENDRON PUBESCENS	Н	Only for use as an active homoeopathic ingredient.  The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron pubescens.
4901	TOXICODENDRON RADICANS	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron radicans.
4902	TOXICODENDRON SUCCEDANEUM	Н	Only for use as an active homoeopathic ingredient.
4903	TRACHELOSPERMUM JASMINOIDES	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4904	TRACHYSPERMUM AMMI	A, E	Only for use in oral medicines when the plant part is fruit or seed.  The medicine requires the following warning statements on the medicine label:  - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)  - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).  Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4905	TRAGACANTH	A, E	
4906	TRAMETES VERSICOLOR	A, H	
4907	TRAMETES VERSICOLOR PROTEOGLYCAN CONCENTRATE	А, Н	Only for use in oral medicines.
4908	TRANS,TRANS-2,4-DECADIEN-1-	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
	AL		permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4909	TRANS,TRANS-2,4-HEXADIENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.  The maximum daily dose must provide no more than 13.5 mg of Trans, Trans-2,4-Hexadienal.
4910	TRANS-1-(2,4,4-TRIMETHYL-2-CYCLOHEXEN-1-YL)-2-BUTEN-1-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
4911	TRANS-2-DECENAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4912	TRANS-2-DODECENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4913	TRANS-2-HEPTEN-1-AL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
4914	TRANS-2-HEXENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4915	TRANS-2-HEXENOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4916	TRANS-2-HEXENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.  If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
4917	TRANS-2-HEXENYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4918	TRANS-2-HEXENYL PHENYLACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4919	TRANS-2-HYDROXYCINNAMIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
4920	TRANS-2-UNDECENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4921	TRANS-3-HEXENOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4922	TRANS-4-DECENAL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4923	TRANS-8-(1-METHYLETHYL)-1-OXASPIRO(4.5)DECAN-2-ONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4924	TRANS-ETHYL 2-OCTENOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4925	TRANS-METHYL-2-HEXENOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.  If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
4926	TREACLE	Е	When for oral or sublingual use, sucrose is a mandatory component of Treacle.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:  - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.  If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:  - (LACT) 'Contains lactose' (or words to that effect).
4927	TREEMOSS ABSOLUTE	Е	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.  When included in a medicine for use on the lips the concentration of treemoss

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			absolute must be no more than 0.02%.
			When for dermal use or use on the hair the concentration of treemoss absolute must be no more than 0.1%
			The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
4928	TREFRIW WELLS MINERAL WATER	A	When for internal use, iron is a mandatory component of Trefriw Wells mineral water.  Solid dosage forms containing more than 5 milligrams of elemental iron in each dosage unit are required to have a child resistant closure.  Liquid Preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.  Only able to be used when presented in single use sachets for therapeutic use as an iron supplement.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4929	TREHALOSE DIHYDRATE	E	When for oral use and the quantity of trehalose dihydrate per maximum recommended daily dose exceeds 20 grams, the quantity of trehalose dihydrate must be declared on the label.
4930	TREMELLA FUCIFORMIS	А, Н	
4931	TRIACETIN	E	
4932	TRIACONTANYL PVP	E	Only for use in topical medicines for dermal application.
4933	TRIADICA SEBIFERA	А, Н	
4934	TRIBASIC POTASSIUM PHOSPHATE	A, E, H	When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of tribasic potassium phosphate.  When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5.
_			When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			11.5.
4935	TRIBASIC SODIUM PHOSPHATE	E	When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.  When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.  When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:  - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).
4936	TRIBEHENIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			6%.
4937	TRIBEHENIN PEG-20 ESTERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 6%.
4938	TRIBULUS TERRESTRIS	A, E, H	
4939	TRIBUTYL ACETYLCITRATE	E.	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4940	TRICALCIUM PHOSPHATE	Е	
4941	TRICAPRYLIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
4942	TRICAPRYLYL CITRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 7%.
4943	TRICETEARETH-4 PHOSPHATE	Е	Only for use in topical medicines for dermal application.
4944	TRICHLOROMETHYLPHENYLC ARBINYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4945	TRICHODERMA VIRIDE	A, E, H	
4946	TRICHOSANTHES KIRILOWII	A, E, H	
4947	TRICLOSAN	Е	The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
4948	TRICYCLODECENYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4949	TRIDECANAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4950	TRIDECETH-4 PHOSPHATE	Е	Only for use in topical medicines for dermal application.
4951	TRIDECETH-6	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye or on damaged skin.
			The concentration in the medicine must be no more than 0.5%.
4952	TRIDECYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4953	TRIDECYL BEHENATE	Е	Behenic acid is a mandatory component of Tridecyl behenate.  Only for use in topical medicines for dermal application.
4954	TRIDECYL NEOPENTANOATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			23%.
4955	TRIDECYL SALICYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4956	TRIDECYL STEARATE	Е	Only for use in topical medicines for dermal application.
4957	TRIDECYL TRIMELLITATE	Е	Only for use in topical medicines for dermal application.
4958	TRIETHOXYCAPRYLYLSILANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
10.70			
4959	TRIETHYL CITRATE	Е	
4960	TRIETHYLENE GLYCOL	Е	
4961	TRIFOLIUM PRATENSE	A, E, H	
4962	TRIFOLIUM REPENS	A, H	
4963	TRIGONELLA FOENUM- GRAECUM	A, E, H	
4964	TRIHYDROXYPALMITAMIDOH YDROXYPROPYL MYRISTYL ETHER	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.02%.
4965	TRIHYDROXYSTEARIN	Е	Only for use in topical medicines for dermal application.
4966	TRIISOCETYL CITRATE	Е	Only for use in topical medicines for dermal application.
4967	TRIISODECYL TRIMELLITATE	E	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4968	TRIISONONANOIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4969	TRIISOSTEARIN	E	Only for use in topical medicines for dermal application.
4970	TRILAURIN	E	Only for use in topical medicines for dermal application.
4971	TRILISA ODORATISSIMA	A, H	
4972	TRILLIUM ERECTUM	A, H	
4973	TRIMETHOXYCAPRYLYL SILANE	Е	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.25%.
4974	TRIMETHYL HYDROXYPENTYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4975	TRIMETHYL UNDECYLENIC ALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4976	TRIMETHYL-BICYCLO- HEPTANE- SPIROCYCLOHEXENONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
4977	TRIMETHYLBENZENEPROPANO L	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4978	TRIMETHYLHEXANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4979	TRIMETHYLOPROPANE TRIOCTANOATE	E	Only for use in topical medicines for dermal application.
4980	TRIMETHYLPENTANEDIOL/ADI PIC ACID/GLYCERIN CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye.  The concentration in the medicine must be no more than 5%.
4981	TRIMETHYLSILOXYSILICATE	Е	Only for use in topical medicines for dermal application.
4982	TRINITROPHENOL	Н	Only for use as an active homoeopathic ingredient.
4983	TRIOCTANOIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 5%.
4984	TRIOCTYLDODECYL CITRATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			12%.
4985	TRIOLEIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.1%.
4986	TRIOSTEUM PERFOLIATUM	A, H	
4987	TRIOXAUNDECANEDIOIC ACID	Е	
4988	TRIPAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance.  If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
4989	TRIPEPTIDE-1	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.  The concentration in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 0.002%.
4990	TRIS-BIPHENYL TRIAZINE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 10%.  When used topically, the dosage form must not be spray.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register of the sun' (or words to this effect).
			sunscreen products and listed in the Register before 1 January 2018, the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
4991	TRISILOXANE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the
			medicine must be no more than 40%.
4992	TRISODIUM EDETATE	Е	Only for use in topical medicines for dermal application.
4993	TRISODIUM ETHYLENEDIAMINE DISUCCINATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 0.2%.
4994	TRISODIUM NTA	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.005%.
4995	TRISTEARIN	Е	
4996	TRITICUM AESTIVUM	A, E, H	Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
4997	TRITICUM DURUM	A, E, H	Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.  When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:  - (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).
4998	TRIUNDECANOIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 11.2%.
4999	TROLAMINE	E	Only for use in topical medicines for dermal application.  The concentration in the medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
5000	TROLAMINE LAURIL SULFATE	Е	Only for use in topical medicines for dermal application.
5001	TROLAMINE SALICYLATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 12%.  When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:  - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and  - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).  When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
5002	TROLLIUS CHINENSIS	A, H	
5003	TROMETAMOL	Е	
5004	TROMETAMOL HYDROCHLORIDE	Е	
5005	TROPAEOLUM MAJUS	A, E, H	
5006	TROPICAL RATTLESNAKE	Н	Only for use as an active homoeopathic ingredient.
5007	TROPOLONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.  The concentration in the medicine must be no more than 0.01%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
5008	TSUGA CANADENSIS	A 11	
3008	I SUGA CANADENSIS	A, H	
5009	TULIPA EDULIS	А, Н	Colchicine is a mandatory component of Tulipa edulis.  The concentration of colchicine in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.
5010	TURMERIC	Е	Permitted for use only in combination with other permitted ingredients as a colour.
5011	TURNERA DIFFUSA	A, E, H	Arbutin is a mandatory component of Turnera diffusa.  The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg/L or 0.0025 % unless used on the hair.  When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.
5012	TURNIP	Е	

Column 1	Column 2 Ingredient Name	Column 3  Purpose of the ingredient in the medicine	Column 4  Specific requirements(s) applying to the ingredient in Column 2
5014	TYPHA ANGUSTIFOLIA	A, H	
5015	TYPHA LATIFOLIA	A, H	
5016	TYPHONIUM GIGANTEUM	A, H	
5017	TYROSINE	A, E	